1
|
Villacampa G, Tung NM, Pernas S, Paré L, Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, Del Monte-Millán M, Marín-Aguilera M, Brasó-Maristany F, Waks AG, Pascual T, Martínez-Sáez O, Vivancos A, Conte PF, Guarneri V, Vittoria Dieci M, Griguolo G, Cortés J, Llombart-Cussac A, Muñoz M, Vidal M, Adamo B, Wolff AC, DeMichele A, Villagrasa P, Parker JS, Perou CM, Fernandez-Martinez A, Carey LA, Mittendorf EA, Martín M, Prat A, Tolaney SM. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer. Ann Oncol 2023; 34:783-795. [PMID: 37302750 PMCID: PMC10735273 DOI: 10.1016/j.annonc.2023.05.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Revised: 05/24/2023] [Accepted: 05/25/2023] [Indexed: 06/13/2023] Open
Abstract
BACKGROUND The HER2DX genomic test predicts pathological complete response (pCR) and survival outcome in early-stage HER2-positive (HER2+) breast cancer. Here, we evaluated the association of HER2DX scores with (i) pCR according to hormone receptor status and various treatment regimens, and (ii) survival outcome according to pCR status. MATERIALS AND METHODS Seven neoadjuvant cohorts with HER2DX and clinical individual patient data were evaluated (DAPHNe, GOM-HGUGM-2018-05, CALGB-40601, ISPY-2, BiOnHER, NEOHER and PAMELA). All patients were treated with neoadjuvant trastuzumab (n = 765) in combination with pertuzumab (n = 328), lapatinib (n = 187) or without a second anti-HER2 drug (n = 250). Event-free survival (EFS) and overall survival (OS) outcomes were available in a combined series of 268 patients (i.e. NEOHER and PAMELA) with a pCR (n = 118) and without a pCR (n = 150). Cox models were adjusted to evaluate whether HER2DX can identify patients with low or high risk beyond pCR status. RESULTS HER2DX pCR score was significantly associated with pCR in all patients [odds ratio (OR) per 10-unit increase = 1.59, 95% confidence interval 1.43-1.77; area under the ROC curve = 0.75], with or without dual HER2 blockade. A statistically significant increase in pCR rate due to dual HER2 blockade over trastuzumab-only was observed in HER2DX pCR-high tumors treated with chemotherapy (OR = 2.36 (1.09-5.42). A statistically significant increase in pCR rate due to multi-agent chemotherapy over a single taxane was observed in HER2DX pCR-medium tumors treated with dual HER2 blockade (OR = 3.11, 1.54-6.49). The pCR rates in HER2DX pCR-low tumors were ≤30.0% regardless of treatment administered. After adjusting by pCR status, patients identified as HER2DX low-risk had better EFS (P < 0.001) and OS (P = 0.006) compared with patients with HER2DX high-risk. CONCLUSIONS HER2DX pCR score and risk score might help identify ideal candidates to receive neoadjuvant dual HER2 blockade in combination with a single taxane in early-stage HER2+ breast cancer.
Collapse
Affiliation(s)
- G Villacampa
- SOLTI Breast Cancer Research Group, Barcelona; Oncology Data Science, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | - S Pernas
- Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona
| | - L Paré
- Reveal Genomics, Barcelona
| | - C Bueno-Muiño
- Medical Oncology Department, Hospital Infanta Cristina (Parla), Fundación de Investigación Biomédica del H.U. Puerta de Hierro, Majadahonda, Madrid
| | - I Echavarría
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | - S López-Tarruella
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | - M Roche-Molina
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | - M Del Monte-Millán
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | | | - F Brasó-Maristany
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - A G Waks
- Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA
| | - T Pascual
- SOLTI Breast Cancer Research Group, Barcelona; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - O Martínez-Sáez
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - A Vivancos
- Cancer Genomics Group, VHIO, Barcelona, Spain
| | - P F Conte
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - V Guarneri
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - M Vittoria Dieci
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - G Griguolo
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - J Cortés
- International Breast Cancer Center, Pangaea Oncology, Quirónsalud Group, Barcelona
| | - A Llombart-Cussac
- Arnau de Vilanova Hospital, Universidad Católica de Valencia, Valencia, Spain
| | - M Muñoz
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - M Vidal
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - B Adamo
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - A C Wolff
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore
| | - A DeMichele
- Department of Oncology, University of Pennsylvania, Philadelphia
| | | | - J S Parker
- Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill
| | - C M Perou
- Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill
| | - A Fernandez-Martinez
- Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill
| | - L A Carey
- Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill
| | - E A Mittendorf
- Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, USA
| | - M Martín
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | - A Prat
- Reveal Genomics, Barcelona; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Institute of Oncology (IOB)-Quirón, Barcelona, Spain.
| | - S M Tolaney
- Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Institute of Oncology (IOB)-Quirón, Barcelona, Spain.
| |
Collapse
|
2
|
Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021; 32:1475-1495. [PMID: 34678411 DOI: 10.1016/j.annonc.2021.09.019] [Citation(s) in RCA: 403] [Impact Index Per Article: 134.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Accepted: 09/30/2021] [Indexed: 12/29/2022] Open
Affiliation(s)
- A Gennari
- Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
| | - F André
- Breast Cancer Unit, Medical Oncology Department, Gustave Roussy-Cancer Campus, Villejuif, France
| | - C H Barrios
- Oncology Research Center, Grupo Oncoclínicas, Porto Alegre, Brazil
| | - J Cortés
- International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain; Scientific Department, Medica Scientia Innovation Research, Valencia, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain
| | - E de Azambuja
- Medical Oncology Department, Institute Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium
| | - A DeMichele
- Hematology/Oncology Department, Hospital of the University of Pennsylvania, Philadelphia, USA
| | - R Dent
- Department of Medical Oncology, National Cancer Centre Singapore, Singapore
| | - D Fenlon
- College of Human and Health Sciences, Swansea University-Singleton Park Campus, Swansea, UK
| | - J Gligorov
- Départment d' Oncologie Médicale, Institut Universitaire de Cancérologie AP-HP, Sorbonne Université, Hôpital Tenon, Paris, France
| | - S A Hurvitz
- Department of Medicine/Division of Hematology Oncology, David Geffen School of Medicine, University of California, Los Angeles, USA; Jonsson Comprehensive Cancer Center, Los Angeles, USA
| | - S-A Im
- Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - D Krug
- Department of Radiation Oncology, University Hospital Schleswig-Holstein-Campus Kiel, Kiely, Germany
| | - W G Kunz
- Department of Radiology, University Hospital, LMU Munich, Munich, Germany
| | - S Loi
- Peter MacCallum Cancer Centre, Melbourne, Australia
| | - F Penault-Llorca
- Centre de Lutte Contre le Cancer Jean Perrin, Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, UMR INSERM-UCA, Clermont Ferrand, France
| | - J Ricke
- Breast Cancer Unit, Medical Oncology Department, Gustave Roussy-Cancer Campus, Villejuif, France; Department of Radiology, University Hospital, LMU Munich, Munich, Germany
| | - M Robson
- Medicine Department, Memorial Sloan Kettering Cancer Center, New York, USA
| | - H S Rugo
- Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - C Saura
- Breast Cancer Program, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - P Schmid
- Centre of Experimental Cancer Medicine, Cancer Research UK Barts Centre, Barts and The London School of Medicine and Dentistry, London, UK
| | - C F Singer
- Center for Breast Health and Department of Obstetrics & Gynecology, Medical University of Vienna, Vienna, Austria
| | - T Spanic
- Europa Donna Slovenia, Slovenia, USA
| | | | - N C Turner
- The Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - G Curigliano
- Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, IRCCS and University of Milano, Milan, Italy
| | - S Loibl
- GBG Forschungs GmbH, Neu-Isenburg, Germany
| | - S Paluch-Shimon
- Sharett Institute of Oncology Department, Hadassah University Hospital & Faculty of Medicine Hebrew University, Jerusalem, Israel
| | - N Harbeck
- Breast Center, Department of Obstetrics & Gynecology and Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany
| |
Collapse
|
3
|
Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. Ann Oncol 2021; 32:642-651. [PMID: 33617937 DOI: 10.1016/j.annonc.2021.02.011] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 02/07/2021] [Accepted: 02/13/2021] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND We proposed that a test for sensitivity to the adjuvant endocrine therapy component of treatment for patients with stage II-III breast cancer (SET2,3) should measure transcription related to estrogen and progesterone receptors (SETER/PR index) adjusted for a baseline prognostic index (BPI) combining clinical tumor and nodal stage with molecular subtype by RNA4 (ESR1, PGR, ERBB2, and AURKA). PATIENTS AND METHODS Patients with clinically high-risk, hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) breast cancer received neoadjuvant taxane-anthracycline chemotherapy, surgery with measurement of residual cancer burden (RCB), and then adjuvant endocrine therapy. SET2,3 was measured from pre-treatment tumor biopsies, evaluated first in an MD Anderson Cancer Center (MDACC) cohort (n = 307, 11 years' follow-up, U133A microarrays), cut point was determined, and then independent, blinded evaluation was carried out in the I-SPY2 trial (n = 268, high-risk MammaPrint result, 3.8 years' follow-up, Agilent-44K microarrays, NCI Clinical Trials ID: NCT01042379). Primary outcome measure was distant relapse-free survival. Multivariate Cox regression models tested prognostic independence of SET2,3 relative to RCB and other molecular prognostic signatures, and whether other prognostic signatures could substitute for SETER/PR or RNA4 components of SET2,3. RESULTS SET2,3 added independent prognostic information to RCB in the MDACC cohort: SET2,3 [hazard ratio (HR) 0.23, P = 0.004] and RCB (HR 1.77, P < 0.001); and the I-SPY2 trial: SET2,3 (HR 0.27, P = 0.031) and RCB (HR 1.68, P = 0.008). SET2,3 provided similar prognostic information irrespective of whether RCB-II or RCB-III after chemotherapy, and in both luminal subtypes. Conversely, RCB was most strongly prognostic in cancers with low SET2,3 status (MDACC P < 0.001, I-SPY2 P < 0.001). Other molecular signatures were not independently prognostic; they could effectively substitute for RNA4 subtype within the BPI component of SET2,3, but they could not effectively substitute for SETER/PR index. CONCLUSIONS SET2,3 added independent prognostic information to chemotherapy response (RCB) and baseline prognostic score or subtype. Approximately 40% of patients with clinically high-risk HR+/HER2- disease had high SET2,3 and could be considered for clinical trials of neoadjuvant endocrine-based treatment.
Collapse
Affiliation(s)
- L Du
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - C Yau
- Department of Surgery, University of California, San Francisco, USA
| | - L Brown-Swigart
- Department of Pathology, University of California, San Francisco, USA
| | - R Gould
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - G Krings
- Department of Pathology, University of California, San Francisco, USA
| | - G L Hirst
- Department of Surgery, University of California, San Francisco, USA
| | - I Bedrosian
- Department of Breast Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - R M Layman
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - J M Carter
- Department of Pathology, Mayo Clinic, Rochester, USA
| | - M Klein
- Department of Pathology, University of Minnesota, Minneapolis, USA
| | - S Venters
- Department of Surgery, University of California, San Francisco, USA
| | - S Shad
- Department of Surgery, University of California, San Francisco, USA
| | | | - A J Chien
- Department of Medicine, University of California, San Francisco, USA
| | - T Haddad
- Department of Medicine, Mayo Clinic, Rochester, USA
| | - C Isaacs
- Department of Medicine, Georgetown University, Washington, USA
| | - L Pusztai
- Department of Medicine, Yale University School of Medicine, New Haven, USA
| | - K Albain
- Department of Medicine, Loyola University, Chicago, USA
| | - R Nanda
- Department of Medicine, University of Chicago, Chicago, USA
| | - D Tripathy
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - M C Liu
- Department of Medicine, Mayo Clinic, Rochester, USA
| | - J Boughey
- Department of Surgery, Mayo Clinic, Rochester, USA
| | - R Schwab
- Department of Medicine, University of California, San Diego, USA
| | - N Hylton
- Department of Radiology, University of California, San Francisco, USA
| | - A DeMichele
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, San Philadelphia, USA
| | | | - D Yee
- Department of Medicine, University of Minnesota, Minneapolis, USA
| | - D Berry
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - L Van't Veer
- Department of Pathology, University of California, San Francisco, USA
| | - V Valero
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - L J Esserman
- Department of Surgery, University of California, San Francisco, USA
| | - W F Symmans
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Pathology, The University of Texas MD Anderson Cancer Center, San Francisco, USA.
| |
Collapse
|
4
|
Rugo H, Cristofanilli M, Loibl S, Harbeck N, DeMichele A, Iwata H, Park Y, Brufsky A, Theall KP, Huang X, McRoy L, Bananis E, Turner N. 322P Prognostic factors for overall survival (OS) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Analyses from PALOMA-3. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.424] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
5
|
Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Huang Bartlett C, Koehler M, Winer EP, Burstein HJ. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol 2019; 30:1514-1520. [PMID: 31250880 DOI: 10.1093/annonc/mdz198] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/09/2023] Open
Abstract
BACKGROUND The CDK4/6 inhibitor palbociclib prolongs progression-free survival in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer when combined with endocrine therapy. This phase II trial was designed to determine the feasibility of adjuvant palbociclib and endocrine therapy for early breast cancer. PATIENTS AND METHODS Eligible patients with HR+/HER2- stage II-III breast cancer received 2 years of palbociclib at 125 mg daily, 3 weeks on/1 week off, with endocrine therapy. The primary end point was discontinuation from palbociclib due to toxicity, non-adherence, or events related to tolerability. A discontinuation rate of 48% or higher would indicate the treatment duration of 2 years was not feasible, and was evaluated under a binomial test using a one-sided α = 0.025. RESULTS Overall, 162 patients initiated palbociclib; over half had stage III disease (52%) and most received prior chemotherapy (80%). A total of 102 patients (63%) completed 2 years of palbociclib; 50 patients discontinued early for protocol-related reasons (31%, 95% CI 24% to 39%, P = 0.001), and 10 discontinued due to protocol-unrelated reasons. The cumulative incidence of protocol-related discontinuation was 21% (95% CI 14% to 27%) at 12 months from start of treatment. Rates of palbociclib-related toxicity were congruent with the metastatic experience, and there were no cases of febrile neutropenia. Ninety-one patients (56%) required at least one dose reduction. CONCLUSION Adjuvant palbociclib is feasible in early breast cancer, with a high proportion of patients able to complete 2 years of therapy. The safety profile in the adjuvant setting mirrors that observed in metastatic disease, with approximately half of the patients requiring dose-modification. As extended duration adjuvant palbociclib appears feasible and tolerable for most patients, randomized phase III trials are evaluating clinical benefit in this population. CLINICALTRIALS.GOV REGISTRATION NCT02040857.
Collapse
Affiliation(s)
- E L Mayer
- Susan F. Smith Center for Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston.
| | - A DeMichele
- Division of Hematology and Oncology, University of Pennsylvania Abramson Cancer Center, Philadelphia
| | - H S Rugo
- Division of Hematology and Medical Oncology, University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco
| | - K Miller
- Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
| | - A G Waks
- Susan F. Smith Center for Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | - S E Come
- Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston
| | - T Mulvey
- Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston
| | - R Jeselsohn
- Susan F. Smith Center for Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | - B Overmoyer
- Susan F. Smith Center for Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | - H Guo
- Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston
| | - W T Barry
- Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston
| | | | | | - E P Winer
- Susan F. Smith Center for Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | - H J Burstein
- Susan F. Smith Center for Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| |
Collapse
|
6
|
Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Diéras V, Moulder S, Lipatov O, Colleoni M, Cristofanilli M, Lu DR, Mori A, Giorgetti C, Iyer S, Bartlett CH, Gelmon KA. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol 2019; 29:669-680. [PMID: 29342248 PMCID: PMC5888946 DOI: 10.1093/annonc/mdx797] [Citation(s) in RCA: 63] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background This report assesses the efficacy and safety of palbociclib plus endocrine therapy (ET) in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC) with or without visceral metastases. Patients and methods Pre- and postmenopausal women with disease progression following prior ET (PALOMA-3; N = 521) and postmenopausal women untreated for ABC (PALOMA-2; N = 666) were randomized 2 : 1 to ET (fulvestrant or letrozole, respectively) plus palbociclib or placebo. Progression-free survival (PFS), safety, and patient-reported quality of life (QoL) were evaluated by prior treatment and visceral involvement. Results Visceral metastases incidence was higher in patients with prior resistance to ET (58.3%, PALOMA-3) than in patients naive to ET in the ABC setting (48.6%, PALOMA-2). In patients with prior resistance to ET and visceral metastases, median PFS (mPFS) was 9.2 months with palbociclib plus fulvestrant versus 3.4 months with placebo plus fulvestrant [hazard ratio (HR), 0.47; 95% confidence interval (CI), 0.35–0.61], and objective response rate (ORR) was 28.0% versus 6.7%, respectively. In patients with nonvisceral metastases, mPFS was 16.6 versus 7.3 months, HR 0.53; 95% CI 0.36–0.77. In patients with visceral disease and naive to ET in the advanced disease setting, mPFS was 19.3 months with palbociclib plus letrozole versus 12.9 months with placebo plus letrozole (HR 0.63; 95% CI 0.47–0.85); ORR was 55.1% versus 40.0%; in patients with nonvisceral disease, mPFS was not reached with palbociclib plus letrozole versus 16.8 months with placebo plus letrozole (HR 0.50; 95% CI 0.36–0.70). In patients with prior resistance to ET with visceral metastases, palbociclib plus fulvestrant significantly delayed deterioration of QoL versus placebo plus fulvestrant, whereas patient-reported QoL was maintained with palbociclib plus letrozole in patients naive to endocrine-based therapy for ABC. Conclusions Palbociclib plus ET prolonged mPFS in patients with visceral metastases, increased ORRs, and in patients previously treated for ABC, delayed QoL deterioration, presenting a standard treatment option among patients with visceral metastases amenable to endocrine-based therapy. Clinical trial registration NCT01942135, NCT01740427
Collapse
Affiliation(s)
- N C Turner
- Toby Robins Breast Cancer Research Centre, Institute of Cancer Research and Royal Marsden Hospital, London, UK.
| | - R S Finn
- Department of Medicine, David Geffen School of Medicine, Los Angeles, USA
| | - M Martin
- Department of Medicine, Hospital Gregorio Marañón, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain
| | - S-A Im
- Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - A DeMichele
- Department of Medicine, University of Pennsylvania, Philadelphia, USA
| | - J Ettl
- Klinik und Poliklinik fuer Frauenheilkunde Klinikum Rechts der Isar, Technische Universitaet Muenchen, Munich, Germany
| | - V Diéras
- Department of Clinical Research, Institut Curie, Paris, France
| | - S Moulder
- Department of Breast Medical Oncology, M.D. Anderson Cancer Center, University of Texas, Houston, USA
| | - O Lipatov
- State Budget Medical Institution Republican Clinical Oncology Dispensary, Ufa, Russia
| | - M Colleoni
- European Institute of Oncology, Milan, Italy
| | - M Cristofanilli
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago
| | - D R Lu
- Pfizer Inc, La Jolla, USA
| | - A Mori
- Pfizer S.r.l, Milan, Italy
| | | | - S Iyer
- Pfizer Inc, New York, USA
| | | | - K A Gelmon
- Department of Medical Oncology, British Columbia Cancer Agency-Vancouver Centre, Vancouver, Canada
| |
Collapse
|
7
|
Silverstein J, Suleiman L, Yau C, Price ER, Singhrao R, Yee D, DeMichele A, Isaacs C, Albain KS, Chien AJ, Forero-Torres A, Wallace AM, Pusztai L, Ellis ED, Elias AD, Lang JE, Lu J, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Berry DA, Asare SM, Esserman LJ, Boughey JC, Mukhtar RA. Abstract P2-14-01: The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-14-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In women with breast cancer receiving neoadjuvant chemotherapy, residual cancer burden (RCB) predicts distant recurrence and survival. In those with high risk tumors, locoregional recurrence (LRR) remains a concern, and has been associated with type of local therapy received. We evaluated the impact of local therapy on LRR in the ISPY-2 TRIAL.
Methods: Data were analyzed in Stata 14.2, using Chi2 test, log rank test, and a Cox proportional hazards model. RCB was considered a categorical variable (0/1 versus 2/3), as described in prior publications. Breast surgery categories were lumpectomy +/- radiotherapy, or mastectomy +/- radiotherapy. Axillary surgery was defined as sentinel lymph node (SLN) surgery (≤6 nodes removed) or axillary dissection (>6 nodes).
Results: Follow up data from the I-SPY2 TRIAL were available for 630 patients (median follow up 2.76 yrs, range 0.4-7.2). Type of local therapy was significantly associated with clinical stage at presentation, with stage III patients most frequently undergoing mastectomy + radiation (p<0.001). Women with higher RCB were more likely to undergo mastectomy than those with lower RCB (61.3% vs 48.8% mastectomy rate, p=0.002), and more likely to receive adjuvant radiotherapy (62.0% vs 53.9%, p=0.048). There was no association between clinical stage, type of surgery, or radiotherapy and LRR (Table). Higher RCB was significantly associated with LRR, with 3 year locoregional recurrence free rate of 95.1% in RCB 0/1 versus 89.9% in RCB 2/3 (p=0.003).
In a Cox model adjusting for clinical stage, tumor subtype, surgical therapy, RCB status, nodal radiation, and age, significant predictors for LRR were tumor subtype and RCB status. Hazard ratio (HR) for LRR in those with RCB 0/1 was 0.39 compared to those with RCB 2/3 (95% CI 0.17-0.87, p=0.021). There was no difference in LRR between breast conservation and mastectomy; within the breast conservation group, those who had lumpectomy alone had higher hazard of LRR compared to those having lumpectomy + radiation (HR 3.1, 95% CI 1.1-9.2, p=0.043).
Conclusions: Extent of surgical therapy was not associated with local tumor control, regardless of advanced tumor stage at presentation. Rather, tumor biology and response to therapy were the best predictors of LRR. These data highlight the opportunity to minimize the morbidity of extensive surgical therapy for patients with excellent response to systemic therapy.
LRR rates by clinical features and treatment status FrequencyLRR RateP valueClinical Stage 0.5I240 (47.5%)5.8% II185 (36.6%)8.7% III80 (15.8%)6.3% Tumor Subtype 0.014ER+PR+Her2-161 (26.4%)3.1% ER+PR-Her2-56 (9.2%)3.6% Her2+176 (28.9%)6.3% Triple negative216 (35.5%)11.1% Local therapy 0.169Lumpectomy85 (13.5%)11.8% Lumpectomy with radiation198 (31.4%)5.6% Mastectomy173 (27.5%)5.2% Mastectomy with radiation174 (27.6%)8.6% Axillary surgery 0.23None5 (0.8%)20% SLN329 (52.2%)5.8% ALND296 (47%)8.5% Axillary radiation 0.535Yes42 (6.7%)9.5% No588 (93.3%)7.0% Axillary management 0.2No surgery or radiation5 (0.8%)20.0% SLN312 (50%)5.3% SLN+Axillary radiation17 (2.7%)8.3% ALND271 (43%)10.3% ALND+Axillary radiation25 (4%)5.4% RCB 0.0020/1293 (50.1%)3.8% 2/3292 (49.9%)10.3%
Citation Format: Silverstein J, Suleiman L, Yau C, Price ER, Singhrao R, Yee D, DeMichele A, Isaacs C, Albain KS, Chien AJ, Forero-Torres A, Wallace AM, Pusztai L, Ellis ED, Elias AD, Lang JE, Lu J, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, I-SPY 2 TRIAL Consortium, Berry DA, Asare SM, Esserman LJ, Boughey JC, Mukhtar RA. The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-14-01.
Collapse
Affiliation(s)
- J Silverstein
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - L Suleiman
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - C Yau
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - ER Price
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - R Singhrao
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - D Yee
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - A DeMichele
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - C Isaacs
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - KS Albain
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - AJ Chien
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - A Forero-Torres
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - AM Wallace
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - L Pusztai
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - ED Ellis
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - AD Elias
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - JE Lang
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - J Lu
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - HS Han
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - AS Clark
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - L Korde
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - R Nanda
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - DW Northfelt
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - QJ Khan
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - RK Viscusi
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - DM Euhus
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - KK Edmiston
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - SY Chui
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - K Kemmer
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - WC Wood
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - JW Park
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - MC Liu
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - O Olopade
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - B Leyland-Jones
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - D Tripathy
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - SL Moulder
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - HS Rugo
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - R Schwab
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - S Lo
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - T Helsten
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - H Beckwith
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - DA Berry
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - SM Asare
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - LJ Esserman
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - JC Boughey
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - RA Mukhtar
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | | |
Collapse
|
8
|
Hylton NM, Symmans WF, Yau C, Li W, Hatzis C, Isaacs C, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal I, Tawfik O, Grasso LeBeau L, Sahoo S, Vinh T, Yang S, Adams A, Chien AJ, Ferero-Torres A, Stringer-Reasor E, Wallace A, Boughey JC, Ellis ED, Elias AD, Lang JE, Lu J, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen PK, van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Sanil A, Berry SM, Abe H, Wolverton D, Crane EP, Ward KA, Nelson M, Niell BL, Oh K, Brandt KR, Bang DH, Ojeda-Fournier H, Eghtedari M, Sheth PA, Bernreuter WK, Umphrey H, Rosen MA, Dogan B, Yang W, Joe B, Yee D, Pusztai L, DeMichele A, Asare SM, Berry DA, Esserman LJ. Abstract P2-07-03: Refining neoadjuvant predictors of three year distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-07-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Patients achieving a pathologic complete response (pCR) following neoadjuvant therapy have significantly improved event-free survival relative to those who do not; and pCR is an FDA-accepted endpoint to support accelerated approval of novel agents/combinations in the neoadjuvant treatment of high risk early stage breast cancer. Previous studies have shown that recurrence risk increased with increasing burden of residual disease (as assessed by the RCB index). As well, these studies suggest that patients with minimum residual disease (RCB-I class) also have favorable outcomes (comparable to those achieving a pCR) within high risk tumor subtypes. In this study, we assess whether integrating RCB with MRI functional tumor volume (FTV), which in itself is prognostic, can improve prediction of distant recurrence free survival (DRFS); and identify a subset of patients with minimal residual disease with comparable DRFS as those who achieved a pCR. Imaging tools can then be used to identify the subset that will do well early and guide the timing of surgical therapy.
Method: We performed a pooled analysis of 596 patients from the I-SPY2 TRIAL with RCB, pre-surgical MRI FTV data and known follow-up (median 2.5 years). We first assessed whether FTV predicts residual disease (pCR or pCR/RCB-I) using ROC analysis. We applied a power transformation to normalize the pre-surgical FTV distribution; and assessed its association with DRFS using a bi-variate Cox proportional hazard model adjusting for HR/HER2 subtype. We also fitted a bivariate Cox model of RCB index adjusting for subtype; and assessed whether adding pre-surgical FTV to this model further improves association with DRFS using a likelihood ratio (LR) test. For the Cox modeling, penalized splines approximation of the transformed FTV and RCB index with 2 degrees of freedom was used to allow for non-linear effects of FTV and RCB on DRFS.
Result: Pre-surgical MRI FTV is significantly associated with DRFS (Wald p<0.00001), and more effective at predicting pCR/RCB-I than predicting pCR alone (AUC: 0.72 vs. 0.65). Larger pre-surgical FTV remains associated with worse DRFS adjusting for subtype (Wald p <0.00001). The RCB index is also significantly associated with DRFS adjusting for subtype (Wald p<0.00001). Adding FTV to a model containing RCB and subtype further improves association with DRFS (LR p=0.0007). RCB-I patients have excellent DRFS (94% at 3 years compared to 95% in the pCR group). Efforts are underway to identify an optimal threshold for dichotomizing pre-surgical FTV and FTV change measures for use in combination with pCR/RCB-I class to generate integrated RCB (iRCB) groups as a composite predictor of DRFS.
Conclusion: Pre-surgical MRI FTV is effective at predicting minimal residual disease (RCB0/I) in the I-SPY 2 TRIAL. Despite the association between FTV and RCB, FTV appears to provide independent added prognostic value (to RCB and subtype), suggesting that integrating MRI volume measures and RCB into a composite predictor may improve DRFS prediction.
Citation Format: Hylton NM, Symmans WF, Yau C, Li W, Hatzis C, Isaacs C, Albain KS, Chen Y-Y, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal I, Tawfik O, Grasso LeBeau L, Sahoo S, Vinh T, Yang S, Adams A, Chien AJ, Ferero-Torres A, Stringer-Reasor E, Wallace A, Boughey JC, Ellis ED, Elias AD, Lang JE, Lu J, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen PK, van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Sanil A, Berry SM, Abe H, Wolverton D, Crane EP, Ward KA, Nelson M, Niell BL, Oh K, Brandt KR, Bang DH, Ojeda-Fournier H, Eghtedari M, Sheth PA, Bernreuter WK, Umphrey H, Rosen MA, Dogan B, Yang W, Joe B, I-SPY 2 TRIAL Consortium, Yee D, Pusztai L, DeMichele A, Asare SM, Berry DA, Esserman LJ. Refining neoadjuvant predictors of three year distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-07-03.
Collapse
Affiliation(s)
- NM Hylton
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - WF Symmans
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - C Yau
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - W Li
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - C Hatzis
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - C Isaacs
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - KS Albain
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - Y-Y Chen
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - G Krings
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - S Wei
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - S Harada
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - B Datnow
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - O Fadare
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - M Klein
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - S Pambuccian
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - B Chen
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - K Adamson
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - S Sams
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - P Mhawech-Fauceglia
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - A Magliocco
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - M Feldman
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - M Rendi
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - H Sattar
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - J Zeck
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - I Ocal
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - O Tawfik
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - L Grasso LeBeau
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - S Sahoo
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - T Vinh
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - S Yang
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - A Adams
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - AJ Chien
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - A Ferero-Torres
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - E Stringer-Reasor
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - A Wallace
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - JC Boughey
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - ED Ellis
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - AD Elias
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - JE Lang
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - J Lu
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - HS Han
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - AS Clark
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - L Korde
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - R Nanda
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - DW Northfelt
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - QJ Khan
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - RK Viscusi
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - DM Euhus
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - KK Edmiston
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - SY Chui
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - K Kemmer
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - WC Wood
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - JW Park
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - MC Liu
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - O Olopade
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - D Tripathy
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - SL Moulder
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - HS Rugo
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - R Schwab
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - S Lo
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - T Helsten
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - H Beckwith
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - PK Haugen
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - LJ van't Veer
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - J Perlmutter
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - ME Melisko
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - A Wilson
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - G Peterson
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - AL Asare
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - MB Buxton
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - M Paoloni
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - JL Clennell
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - GL Hirst
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - R Singhrao
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - K Steeg
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - JB Matthews
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - A Sanil
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - SM Berry
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - H Abe
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - D Wolverton
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - EP Crane
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - KA Ward
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - M Nelson
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - BL Niell
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - K Oh
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - KR Brandt
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - DH Bang
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - H Ojeda-Fournier
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - M Eghtedari
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - PA Sheth
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - WK Bernreuter
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - H Umphrey
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - MA Rosen
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - B Dogan
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - W Yang
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - B Joe
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - D Yee
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - L Pusztai
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - A DeMichele
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - SM Asare
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - DA Berry
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | - LJ Esserman
- Avera Cancer Institute Center for Precision Oncology, Sioux Falls, ND; Berry Consultants, LLC, Houston, TX; CTEP, National Cancer Institute, Bethesda, MD; Emory University, Atlanta, GA; Georgetown University, Washington, DC; Inova Health System, Fairfax, VA; Johns Hopkins Medicine, Baltimore, MD; Loyola University, Maywood, IL; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Mayo Clinic, Rochester, MN; Moffitt Cancer Center, Tampa, FL; National Breast Cancer Coalition, Washington, DC; Oregon Health & Science University, Portland, OR; Quantum Leap Healthcare Collaborative, San Francisco, CA; Swedish Cancer Institute, Seattle, WA; The University of Chicago Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Arizona, Tuczon, AZ; University of California, San Diego, La Jolla, CA; University of California, San Francisco, San Francisco, CA; University of Colorado, Denver, Aurora, CO; University of Kansas, Westwood, KS; University of Pennsylvania, Philade
| | | |
Collapse
|
9
|
DeMichele A. Abstract ES9-1: Optimizing treatment of early stage triple negative breast cancer: Clinical challenges and new scientific horizons. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-es9-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
“Triple negative” breast cancer (TNBC) as defined by the lack of estrogen and progesterone receptors and absence of Her2-overexpression, is challenging due to its aggressive natural history and limited treatment options. However, significant progress has been made in the last decade in understanding the biological diversity of TNBC, its prognosis and approaches to successful treatment. For example, molecular classification by gene expression studies initially identified a basal molecular subtype enriched for TNBC, which was further refined to additional include 4 major subtypes: basal-like, mesenchymal, luminal androgen receptor and immune-enriched. In addition, clear associations between TNBC and mutations in DNA-repair-related genes, especially BRCA-1 and BRCA-2 have been elucidated. These findings have subsequently guided therapeutic development.
The early-stage setting has been the focus of much of this work, as it is clear that patients who have tumors that respond vigorously to chemotherapy preoperatively have a reduced likelihood of later metastatic recurrence compared to those who have poorly-responsive disease. Capitalizing on this knowledge, trials in the neoadjuvant setting have defined the importance of pathologic complete response (pCR) as a surrogate endpoint, and have shed light on differential effects of standard therapy (such as platinums), development of new targeted therapies (such as PARP inhibitors) and the role of immunotherapy.
The high rate of observed recurrence in patients who have high stage disease at diagnosis, or, in particular, residual disease after neoadjuvant therapy, has also led to the launch of clinical trials in the adjuvant and post-neoadjvuant setting designed to specifically address micrometastatic minimal residual disease and therapy resistance. The advantage of the post-neoadjvuant approach to trials amongst patients with residual disease is to decrease the size of adjuvant trials, and allow them to be focused within populations most at risk of recurrence, sparing those with good prognosis the need for additional, potentially toxic treatment.
Despite this progress, there are still many unanswered questions regarding optimal therapy and potential to improve outcomes in TNBC. This session will review the state of the science with regard to biology, new treatment approaches, and the value of both the neoadjuvant and post-neoadjvuant settings in developing optimal approaches to tailor therapy on the basis of risk stratification, reduce recurrence, and improve outcomes for women presenting with triple negative breast cancer.
Citation Format: DeMichele A. Optimizing treatment of early stage triple negative breast cancer: Clinical challenges and new scientific horizons [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr ES9-1.
Collapse
Affiliation(s)
- A DeMichele
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
10
|
Schwab R, Clark A, Yau C, Wolf D, Chien AJ, Majure M, Ewing C, Wallace A, Roesch E, Helsten T, Forero A, Stringer-Reasor E, Vaklavas C, Nanda R, Jaskowiak N, Boughey J, Haddad T, Han H, Lee C, Albain K, Isaacs C, Elias A, Ellis E, Shah P, Lang J, Lu J, Tripathy D, Kemmer K, Yee D, Haley B, Korde L, Edmiston K, Northfelt D, Viscusi R, Khan Q, Symmans WF, Perlmutter J, Hylton N, Rugo H, Melisko M, Wilson A, Singhrao R, Asare S, van't Veer L, DeMichele A, Berry D, Esserman L. Abstract P1-15-02: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-15-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Schwab R, Clark A, Yau C, Wolf D, Chien AJ, Majure M, Ewing C, Wallace A, Roesch E, Helsten T, Forero A, Stringer-Reasor E, Vaklavas C, Nanda R, Jaskowiak N, Boughey J, Haddad T, Han H, Lee C, Albain K, Isaacs C, Elias A, Ellis E, Shah P, Lang J, Lu J, Tripathy D, Kemmer K, Yee D, Haley B, Korde L, Edmiston K, Northfelt D, Viscusi R, Khan Q, I-SPY 2 Consortium, Symmans WF, Perlmutter J, Hylton N, Rugo H, Melisko M, Wilson A, Singhrao R, Asare S, van't Veer L, DeMichele A, Berry D, Esserman L. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-15-02.
Collapse
Affiliation(s)
- R Schwab
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - A Clark
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - C Yau
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - D Wolf
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - AJ Chien
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - M Majure
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - C Ewing
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - A Wallace
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - E Roesch
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - T Helsten
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - A Forero
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - E Stringer-Reasor
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - C Vaklavas
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - R Nanda
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - N Jaskowiak
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - J Boughey
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - T Haddad
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - H Han
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - C Lee
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - K Albain
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - C Isaacs
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - A Elias
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - E Ellis
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - P Shah
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - J Lang
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - J Lu
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - D Tripathy
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - K Kemmer
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - D Yee
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - B Haley
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - L Korde
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - K Edmiston
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - D Northfelt
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - R Viscusi
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - Q Khan
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - WF Symmans
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - J Perlmutter
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - N Hylton
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - H Rugo
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - M Melisko
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - A Wilson
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - R Singhrao
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - S Asare
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - L van't Veer
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - A DeMichele
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - D Berry
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | - L Esserman
- University of California San Diego, La Jolla, CA; University of Pennsylvania, Philadelphia, PA; University of California San Francisco, San Francisco, CA; Quantum Leap Health Care Collaborative, San Francisco, CA; University of Alabama Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Rochester, Rochester, MN; Moffitt Cancer Center, Tampa, FL; Loyola University, Chicago, IL; Georgetown University, Washington, DC; University of Colorado Denver, Denver, CO; Swedish Cancer Institute, Seattle, WA; University of Southern California, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX; Oregon Health and Sciences University, Portland, OR; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; CTEP, National Cancer Institute, Bethesda, Washington DC; Mayo Scottsdale, Scottsdale, AZ; University of Arizona, Tuscon, AZ; University of Kansas, Lawrence, KS; Berry Consultants, LLC, Houston, TX; Gemini Group, Ann Arbor; Inova Health System, Fairfax, VA
| | | |
Collapse
|
11
|
Wolf DM, Yau C, Wulfkuhle J, Petricoin E, Campbell M, Brown-Swigart L, Hirst G, Asare S, Zhu Z, Lee EP, Delson A, Pohlmann P, Hylton N, Liu MC, Symmans F, DeMichele A, Yee D, Berry D, Esserman L, van 't Veer L. Abstract P3-10-02: Identifying breast cancer molecular phenotypes to predict response in a modern treatment landscape: Lessons from ˜1000 patients across 10 arms of the I-SPY 2 TRIAL. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-10-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The explosion in new treatment options targeting immune checkpoints, HER signaling, DNA repair deficiency, AKT, and other pathways calls for updated breast cancer subtypes beyond HR and HER2 status to predict which patients will respond to which treatments. Here we leverage the I-SPY 2 TRIAL biomarker program over the past 8 years across 10 treatment arms to elucidate a minimal set of biomarkers that may improve response prediction in a modern treatment context, and to investigate which new patient phenotypes are identified by these response-predictive biomarkers.
Methods: 986 patients were considered in this analysis. Treatments included paclitaxel alone (or with trastuzumab (H) in HER2+) or combined with investigational agents: veliparib/carboplatin (VC); neratinib; MK2206; ganitumab; ganetespib; AMG386; TDM1/pertuzumab (P); H/P; and pembrolizumab (Pembro). 24 prospectively defined, mechanism-of-action and pathway-based expression and phospho-protein signatures/biomarkers assayed from pre-treatment biopsies were previously found to be predictive in a particular agent/arm in pre-specified analysis. Here we evaluate these biomarkers in all patients. We assessed association between each biomarker and response in the population as a whole and within each arm and HR/HER2 subtype using a logistic model. To identify optimal dichotomizing thresholds for select biomarkers, 2-fold cross-validation was repeated 500 times. Our analysis is exploratory and does not adjust for multiplicities.
Results: Our initial set of 24 predictive biomarkers reflects DNA repair deficiency (n=2), immune activation (n=7), ER signaling (n=2), HER2 signaling (n=4), proliferation (n=2), phospho-activation of AKT/mTOR (n=2), and ANG/TIE2 (n=1) pathways, among others. Biomarkers reflecting similar biology are correlated and cluster together. We make use of this correlation structure to reduce the dimensionality of the biomarker set to five predictive signals: proliferation, DNA repair deficiency (DRD), immune-engaged (Immune+), luminal/ER (lum), and HER2-activated. These biomarkers, when dichotomized, identify patient groups with differential predicted sensitivities to I-SPY 2 agents and are present at different proportions within receptor subtypes. For instance, in the HER2- subset, Immune+/DRD+ patients are predicted sensitive to both VC and Pembro, and account for 39% of TN, but only 12% of HR+HER2-. On the other end of the spectrum, only 17% of TN are Immune-/DRD-, compared to the majority (56%) of HR+HER2-. There are also subsets of patients positive for only one marker. For the HER2+ subset, 67% are HER2-activated+, and 25% lum+; of these HER2-activated+ patients are more likely to be Immune+ (44%), vs 23% in lum+. HER2-activated+/Immune+ patients have higher predicted sensitivity to HER2-targeted agents than lum+ or Immune- patients.
In all, these molecular phenotypes predict sensitivity to one or more I-SPY 2 investigational agents for 75% of the ˜ 1000 patients.
Conclusion: Molecular phenotypes reflecting proliferation, immune engagement, HER2-activation, luminal/ER-signaling, and DNA repair deficiency may provide a roadmap to guide treatment prioritization for emerging therapeutics.
Citation Format: Wolf DM, Yau C, Wulfkuhle J, Petricoin E, Campbell M, Brown-Swigart L, Hirst G, Asare S, Zhu Z, Lee EP, Delson A, Pohlmann P, I-SPY 2 TRIAL Consortium, Hylton N, Liu MC, Symmans F, DeMichele A, Yee D, Berry D, Esserman L, van 't Veer L. Identifying breast cancer molecular phenotypes to predict response in a modern treatment landscape: Lessons from ˜1000 patients across 10 arms of the I-SPY 2 TRIAL [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-10-02.
Collapse
Affiliation(s)
- DM Wolf
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - C Yau
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - J Wulfkuhle
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - E Petricoin
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - M Campbell
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - L Brown-Swigart
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - G Hirst
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - S Asare
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - Z Zhu
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - EP Lee
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - A Delson
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - P Pohlmann
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - N Hylton
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - MC Liu
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - F Symmans
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - A DeMichele
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - D Yee
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - D Berry
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - L Esserman
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - L van 't Veer
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | | |
Collapse
|
12
|
Maity A, Mick R, Huang A, George S, Farwell M, Lukens J, Berman A, Mitchell T, Bauml J, Schuchter L, O'Hara M, Lin L, DeMichele A, Christodouleas J, Haas N, Patsch D, Hahn S, Minn A, Wherry E, Vonderheide R. A Phase I Trial of Pembrolizumab with Hypofractionated Radiation Therapy (HFRT) in Patients with Metastatic Cancers. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
13
|
Martei Y, Grover S, Bilker W, Setlhako D, Ralefala T, Manshimba P, Gross R, Shulman L, DeMichele A. Impact of Chemotherapy Stock-Out on Standard Therapy Delivery Among Cancer Patients in Botswana. J Glob Oncol 2018. [DOI: 10.1200/jgo.18.30500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Background: Cancer drug shortages represent a complex global issue with potentially adverse survival outcomes. Up to 98% of oncologists and pharmacists surveyed in North America reported at least 1 drug shortage in the prior year and 66% reported at least one patient who had clinical care impacted by the shortage. In low- and middle-income countries (LMICs), these shortages are even more frequent. No studies to our knowledge have evaluated the impact of chemotherapy stock-out on receipt of standard cancer therapy in LMICs. Aim: Quantify the association between the duration of chemotherapy stock-out and the risk of having a suboptimal therapy delivery event, compared with standard delivery of therapy among cancer patients in Botswana. Methods: Prevalent cohort study of patients with cervical, breast, prostate, esophagus, Kaposi sarcoma, head and neck cancers, lung, uterine, ovarian and colorectal cancers who received any systemic therapy between 01/01/16-12/31/16 at Princess Marina Hospital, Botswana. Primary exposure was stock-out duration per cycle interval calculated by generating a code for the six different patterns for chemotherapy stock-out, using stock data at the Central Medical Stores. Primary outcome was suboptimal therapy delivery defined as a dose reduction, dose delay or switch in intended therapy. We measured statistical associations using two sample t-test and mixed effects univariate and multivariate logistic regression models. Results: 378 patients were identified who met diagnostic criteria and received systemic chemotherapy in 2016. Of these, 293 received commonly prescribed standard regimens who contributed 1452 cycle intervals and were included in our analysis. Majority of the patients (48%) had breast cancer. The mean duration of stock-out for receipt of standard therapy without events was 3.2 days (95% CI: 2.8-3.7) compared with 7.8 days for patients who had a suboptimal therapy delivery event (95% CI: 6.6-9) ( P < 0.0001). Male sex, age < 65 and HIV-positive status were also significantly associated with an increased risk of experiencing dose reduction, change in therapy or switch in therapy. Adjusting for these factors in a mixed effects logistic regression, each week of stock-out was independently associated with an 80% increased risk of having a suboptimal therapy delivery event (OR=1.8 (95% CI: 1.6-2.0, P < 0.0001)). Conclusion: Chemotherapy stock-out is independently associated with an 80% increased risk of a patient experiencing dose reduction, change in therapy or delay in therapy. The risk increases with longer duration of stock out. Given prior data showing that these events lead to worse survival outcomes, our further analysis is focusing on quantifying risk of stock-out on survival outcomes in this population. to determine whether interventions promoting standard therapy delivery are warranted to optimize survival outcomes.
Collapse
Affiliation(s)
- Y. Martei
- University of Pennsylvania, Medicine, Hematology-Oncology Division, Philadelphia, PA
| | - S. Grover
- University of Pennsylvania, Medicine, Hematology-Oncology Division, Philadelphia, PA
| | - W. Bilker
- University of Pennsylvania, Medicine, Hematology-Oncology Division, Philadelphia, PA
| | - D. Setlhako
- University of Pennsylvania, Medicine, Hematology-Oncology Division, Philadelphia, PA
| | - T. Ralefala
- University of Pennsylvania, Medicine, Hematology-Oncology Division, Philadelphia, PA
| | - P. Manshimba
- University of Pennsylvania, Medicine, Hematology-Oncology Division, Philadelphia, PA
| | - R. Gross
- University of Pennsylvania, Medicine, Hematology-Oncology Division, Philadelphia, PA
| | - L. Shulman
- University of Pennsylvania, Medicine, Hematology-Oncology Division, Philadelphia, PA
| | - A. DeMichele
- University of Pennsylvania, Medicine, Hematology-Oncology Division, Philadelphia, PA
| |
Collapse
|
14
|
Cristofanilli M, Slamon D, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Turner N. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Loibl S, Metzger O, Mandrekar S, Mundhenke C, Seiler S, Valagussa P, DeMichele A, Lim E, Tripathy D, Winer E, Huang C, Carey L, Francis P, Miller K, Goetz M, Prat A, Loi S, Krop I, Gianni L, Ciruelos E. PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.357] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Bardia A, Yardley DA, Hurvitz S, Wright G, Moroose R, Ma C, Hart L, Tan-Chiu E, Blau S, Sanft T, Dichmann R, Zelnak A, DeMichele A, Clark A, Small T, Tucci C, Samant TS, Purkayastha D, Karuturi M, Moulder S. Abstract PD5-11: Not presented. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd5-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- A Bardia
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - DA Yardley
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Hurvitz
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - G Wright
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - R Moroose
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - C Ma
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Hart
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - E Tan-Chiu
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Blau
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - T Sanft
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - R Dichmann
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A Zelnak
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A DeMichele
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A Clark
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - T Small
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - C Tucci
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - TS Samant
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - D Purkayastha
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - M Karuturi
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Moulder
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
17
|
Metzger-Filho O, Mandrekar S, Loibl S, Ciruelos E, Gianni L, Lim E, Miller K, Huang C, Koehler M, Francis P, Valagussa P, Goel S, Prat A, Goetz M, Loi S, Krop I, Carey L, Lanzillotti J, Winer E, Tripathy D, DeMichele A. Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-05-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Pre-clinical data and initial results from clinical studies point to the added benefit of CDK4/6 inhibition when combined with anti-HER2 tx. The current study is designed to evaluate the added benefit of palbociclib when given in combination with anti-HER2 and endocrine tx maintenance in the 1st†line setting of metastatic HER2+HR+ breast cancer.
Trial design
PATINA is an international, open-label, pivotal Phase III study. Primary objective is to demonstrate that the combination of palbociclib with anti-HER2 plus endocrine tx is superior to anti-HER2 plus endocrine tx in prolonging PFS. Sample size is 496 pts. The study starts after completion of 6-8 cycles of chemotherapy-containing anti-HER2 tx for metastatic breast cancer in the 1st line setting. Pts are eligible provided they are without evidence of disease progression by local assessment (i.e. CR, PR or SD). To account for the need for less intense tx regimens for a subset of pts diagnosed with HER2+ER+ disease, clinicians may recommend the combination of trastuzumab with either a taxane or vinorelbine prior to study initiation. Clinicians might also choose a non-pertuzumab option for pts previously treated with pertuzumab in the neo(adjuvant) setting. Secondary objectives include measures of tumor control (OR, CBR, DOR), OS, safety and QOL. The translational science main objective is to compare PFS estimates according to PIK3CA mutation status assessed by cfDNA analysis. Endocrine tx options are AI or fulvestrant. Premenopausal pts must receive ovarian suppression. The study has a 90% power to detect a hazard ratio of 0.667 in favor of the palbociclib arm. Pts approached to participate in AFT-38 will be asked to indicate on the informed consent forms whether remaining biospecimens and clinical data from the control arm of the study can be shared with the Mastering Breast Cancer (MBC) Initiative. The overarching purpose of the MBC is to create a mechanism for understanding the natural history of metastatic breast cancer by cataloguing longitudinally studied tumor-specific markers and treatment effects.
ClinicalTrials.gov Identifier: NCT02947685
Citation Format: Metzger-Filho O, Mandrekar S, Loibl S, Ciruelos E, Gianni L, Lim E, Miller K, Huang C, Koehler M, Francis P, Valagussa P, Goel S, Prat A, Goetz M, Loi S, Krop I, Carey L, Lanzillotti J, Winer E, Tripathy D, DeMichele A. PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-05-07.
Collapse
Affiliation(s)
- O Metzger-Filho
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - S Mandrekar
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - S Loibl
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - E Ciruelos
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - L Gianni
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - E Lim
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - K Miller
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - C Huang
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - M Koehler
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - P Francis
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - P Valagussa
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - S Goel
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - A Prat
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - M Goetz
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - S Loi
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - I Krop
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - L Carey
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - J Lanzillotti
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - E Winer
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - D Tripathy
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| | - A DeMichele
- Alliance Foundation Trials; German Breast Group; SOLTI; Australia & New Zealand Breast Cancer Trials Group; Fondazonie Michelangelo; Pfizer; prECOG
| |
Collapse
|
18
|
DeMichele A, Soucier-Ernst DJ, Clark C, Shih N, Stavropoulos W, Maxwell KN, Feldman M, Lierbamen D, Morrissette JJD, Paul MR, Pan TC, Wang J, Belka GK, Chen Y, Yee S, Carpenter E, Fox K, Matro J, Clark A, Shah P, Domchek S, Bradbury A, Chodosh L. Abstract OT2-06-03: METAMORPH: METAstatic markers of recurrent tumor PHenotype for breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot2-06-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Up to 30% of patients diagnosed with breast cancer will develop recurrent disease within their lifetime, and currently this form of the disease is incurable. There are unmet needs to better understand underlying metastatic biology, identify new therapeutic targets and develop better methods for monitoring changes in disease, both to monitor response and elucidate resistance mechanisms. To address these needs, the METAMORPH Study encompasses a comprehensive approach that combines serial molecular tissue profiling at the RNA and DNA level with circulating markers (DTCs, CTCs, plasma tumor DNA), and ongoing assessment of therapeutic response.
METAMORPH is a prospective cohort study of women with suspected or confirmed recurrent breast cancer and accessible tumor by standard clinical biopsy, who are enrolled at the University of Pennsylvania prior to starting a new therapy for recurrent metastatic disease. The aims of this trial are to (1) evaluate the mechanisms through which recurrent breast cancer are genetically distinct from the primary tumor, (2) evaluate the circulating tumor biomarker trajectory of recurrent disease, (3) elucidate “escape pathways” of progressing tumors that emerge during the selective pressure of therapy, and (4) explore clinical utility of tumor and blood testing. The study protocol integrates research aims into clinical care, including a standardized approach to disease assessment and biopsy, pathologic confirmation of histology and receptor subtype, panel-based CLIA-approved genomic profiling, collection of research specimens, and standardized reporting of results, which are returned to patients and physicians. Patients are followed for treatment and outcome, and serial samples are collected at progression. A companion protocol, COMET, provides education about genomic testing and assesses patient understanding and impact of results. To date, 155 patients have enrolled, 142 (92%) have been biopsied, 120 (77%) have had sufficient DNA for molecular profiling and 109 (70%) have had genomic panel testing. Accrual is ongoing, with an initial target of 300 patients. Multiple sites within the UPHS Health System are enrolling. Contact information: angela.demichele@uphs.upenn.edu.
Key words: Metastatic disease, tumor profiling.
Citation Format: DeMichele A, Soucier-Ernst DJ, Clark C, Shih N, Stavropoulos W, Maxwell KN, Feldman M, Lierbamen D, Morrissette JJD, Paul MR, Pan T-C, Wang J, Belka GK, Chen Y, Yee S, Carpenter E, Fox K, Matro J, Clark A, Shah P, Domchek S, Bradbury A, Chodosh L. METAMORPH: METAstatic markers of recurrent tumor PHenotype for breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT2-06-03.
Collapse
Affiliation(s)
- A DeMichele
- University of Pennsylvania, Philadelphia, PA
| | | | - C Clark
- University of Pennsylvania, Philadelphia, PA
| | - N Shih
- University of Pennsylvania, Philadelphia, PA
| | | | - KN Maxwell
- University of Pennsylvania, Philadelphia, PA
| | - M Feldman
- University of Pennsylvania, Philadelphia, PA
| | - D Lierbamen
- University of Pennsylvania, Philadelphia, PA
| | | | - MR Paul
- University of Pennsylvania, Philadelphia, PA
| | - T-C Pan
- University of Pennsylvania, Philadelphia, PA
| | - J Wang
- University of Pennsylvania, Philadelphia, PA
| | - GK Belka
- University of Pennsylvania, Philadelphia, PA
| | - Y Chen
- University of Pennsylvania, Philadelphia, PA
| | - S Yee
- University of Pennsylvania, Philadelphia, PA
| | - E Carpenter
- University of Pennsylvania, Philadelphia, PA
| | - K Fox
- University of Pennsylvania, Philadelphia, PA
| | - J Matro
- University of Pennsylvania, Philadelphia, PA
| | - A Clark
- University of Pennsylvania, Philadelphia, PA
| | - P Shah
- University of Pennsylvania, Philadelphia, PA
| | - S Domchek
- University of Pennsylvania, Philadelphia, PA
| | - A Bradbury
- University of Pennsylvania, Philadelphia, PA
| | - L Chodosh
- University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
19
|
Campbell M, Yau C, Borowsky A, Vandenberg S, Wolf D, Rimm D, Nanda R, Liu M, Brown-Swigart L, Hirst G, Asare S, van't Veer L, Yee D, DeMichele A, Berry D, Esserman L. Abstract PD6-08: Analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd6-08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pembrolizumab (Pembro), an anti-PD-1 immune checkpoint inhibitor, has been approved for the treatment of a variety of cancers including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and urothelial carcinoma. Pembro was recently evaluated in HER2- breast cancer patients in the neoadjuvant I-SPY 2 TRIAL and graduated in the triple negative (TN), HR+HER2-, and HER2- signatures. HER2- patients were randomized to receive Pembro+paclitaxel followed by doxorubicin/cyclophosphamide (P+T -> AC) vs. T -> AC. We and others have shown that TN breast cancers tend to have high numbers of immune infiltrates, including T cells and tumor associated macrophages (TAMs). We evaluated expression signatures representing 14 immune cell types (TILs, T cells, CD8 T cells, exhausted T cells, Th1, Tregs, cytotoxic cells, NK, NK CD56dim, dendritic cells, mast cells, B cells, macrophages, and neutrophils) as specific predictors of response to Pembro.
Methods: Data from 248 patients (Pembro: 69; controls: 179) were available. Pre-treatment biopsies were assayed using Agilent gene expression arrays. Signature scores are calculated by averaging cell type specific genes. All I-SPY 2 qualifying biomarker analyses follow a pre-specified analysis plan. We used logistic modeling to assess biomarker performance. A biomarker is considered a specific predictor of Pembro response if it associates with response in the Pembro arm but not the control arm, and if the biomarker x treatment interaction is significant (likelihood ratio test, p<0.05). This analysis is also performed adjusting for HR status as covariates, and within receptor subsets. For successful biomarkers, we use Bayesian modeling to estimate the pCR rates of 'predicted sensitive' patients in each arm. Our statistics are descriptive rather than inferential and do not adjust for multiplicities of other biomarkers outside this study.
Results: 10 out of the 14 cell-type signatures tested are associated with response in the Pembro arm. Higher expression levels of 9 of these cell-type signatures are associated with higher pCR rates (T cells, exhausted T cells, Th1, cytotoxic cells, NK, NK CD56dim, dendritic cells, B cells, and macrophages), whereas higher mast cell signature expression is associated with non-pCR. Interestingly, many of these same signatures also associate or trend towards association with response in the control arm; and in a model adjusting for HR status, only 3 of these signatures (Th1, B cells and dendritic cells) show significant interaction with treatment. Within the whole population and the TN subtype, the dendritic cell signature is the strongest predictor of specific response to Pembro (OR/1SD: 4.04 and 4.4, LR p < 0.001 overall and in TN). Although other immune signatures (T cells, exhausted T cells, NK, and macrophages) also associate with response in the Pembro arm in the TN subtype, only the dendritic cell and Th1 signatures have a significant interaction with treatment. In contrast, in the HR+HER2- subtype, only 3 signatures (Th1, B cells, and mast cells) associate with response to Pembro; but none of these signatures have significant interaction with treatment. Of note, in both the Pembro and control arms, HR+HER2- patients with higher average mast cell marker expression have lower pCR rates (OR/1SD: 0.33 and 0.51, LRp: 0.006 and 0.04 in Pembro and control arm).
Conclusion: As expected, multiple immune cell expression signatures are predictive of response in the Pembro arm; but only dendritic cells and Th1 cells are specific to Pembro in both the population as a whole and the TN subtype. Interestingly, the presence of mast cells may impede response, especially in HR+HER2- patients. Correlation of these signatures with multiplex-IF immune markers is pending.
Citation Format: Campbell M, Yau C, Borowsky A, Vandenberg S, Wolf D, Rimm D, Nanda R, Liu M, Brown-Swigart L, Hirst G, Asare S, van't Veer L, Yee D, DeMichele A, Berry D, Esserman L. Analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD6-08.
Collapse
Affiliation(s)
- M Campbell
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - C Yau
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - A Borowsky
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - S Vandenberg
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - D Wolf
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - D Rimm
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - R Nanda
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - M Liu
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - L Brown-Swigart
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - G Hirst
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - S Asare
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - L van't Veer
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - D Yee
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - A DeMichele
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - D Berry
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| | - L Esserman
- University of California, San Francisco; University of California, Davis; Yale University; University of Chicago; Mayo Clinic Cancer Center; University of Minnesota; University of Pennsylvania; University of Texas
| |
Collapse
|
20
|
Mayer E, DeMichele A, Gnant M, Barry W, Pfeiler G, Metzger O, Burstein H, Miller K, Rastogi P, Loibl S, Goulioti T, Zardavas D, Fesl C, Koehler M, Huang-Bartlett C, Huang X, Piccart M, Winer E, Wolff A. Abstract OT3-05-08: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-05-08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Cell cycle inhibition is a proven target for novel cancer therapeutics. Palbociclib (P) is an orally active inhibitor of CDK4/6, and arrests the cell cycle at the G1-S transition. P in combination with endocrine therapy (ET) has demonstrated efficacy in phase II and III randomized trials for patients with newly diagnosed and recurrent hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast cancer (MBC), and is approved in these settings. Given confirmed benefits of P and ET for MBC, the PALLAS study was designed to determine if the addition of P to adjuvant ET improves outcomes over ET alone in HR+/HER2- early breast cancer.
Trial Design:
PALLAS is an international open-label phase III trial randomizing (1:1) patients (pts) to 2 years of P (125 mg daily, 21 days on 7 days off in a 28-day cycle) combined with at least 5 years of provider choice ET (AI, tamoxifen, +/- LHRH agonist), versus ET alone. The primary objective of the study is to compare invasive disease-free survival (iDFS) for the combination of P and ET, versus ET alone. Secondary objectives include comparison of iDFS excluding cancer of non-breast origin, DRFS, LRRFS, OS, as well as safety. The principal objective of the translational investigations is to determine the predictive or prognostic utility of defined genomic subgroups with respect to iDFS and OS. Additional objectives include evaluation of cfDNA and tissue biomarkers predictive of benefit or resistance, pharmacogenomics, adherence, and patient-reported QOL. Eligible pts are pre- or post-menopausal women or men with stage II-III, HR+/HER2- breast cancer. Patients may have already initiated ET, but must be randomized within 12 months of diagnosis and 6 months of initiation of adjuvant ET. Trial sample size is 4600 pts and stage IIA pts will be capped at a total accrual of 1000 pts. Interim analyses for safety, futility/efficacy and sample size re-estimation are planned. PALLAS opened in 9/2015 and accrual is ongoing. Contact information: emayer@partners.org
Key words: palbociclib, CDK4/6 inhibition, HR+/HER2- early breast cancer, adjuvant endocrine therapy.
Citation Format: Mayer E, DeMichele A, Gnant M, Barry W, Pfeiler G, Metzger O, Burstein H, Miller K, Rastogi P, Loibl S, Goulioti T, Zardavas D, Fesl C, Koehler M, Huang-Bartlett C, Huang X, Piccart M, Winer E, Wolff A. PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-05-08.
Collapse
Affiliation(s)
- E Mayer
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - A DeMichele
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - M Gnant
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - W Barry
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - G Pfeiler
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - O Metzger
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - H Burstein
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - K Miller
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - P Rastogi
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - S Loibl
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - T Goulioti
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - D Zardavas
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - C Fesl
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - M Koehler
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - C Huang-Bartlett
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - X Huang
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - M Piccart
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - E Winer
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - A Wolff
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| |
Collapse
|
21
|
Paul MR, Pan TC, Pant D, Belka GK, Chen Y, Shih N, Lieberman D, Morrissette JJD, Soucier-Ernst D, Clark C, Stavropoulos W, Maxwell K, Feldman M, DeMichele A, Chodosh LA. Abstract PD8-04: Evolutionary history and genomic landscape of metastatic breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd8-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The majority of deaths from breast cancer are due to distant metastatic disease. Despite this, few systematic genomic analyses have been performed on metastatic tumors. This results from the relative difficulty of performing biopsies on metastatic tumors, as well as the uncertainty regarding genomic determinism, according to which the majority of actionable mutations present in metastases can be discovered in the primary tumor.
Methods: “METAMORPH” is an ongoing prospective cohort study of women with suspected or confirmed recurrent breast cancer enrolled prior to starting a new therapy for recurrent metastatic disease. Biopsies of metastatic lesions were performed under radiologic guidance, and archival primary tumors were subsequently obtained. WES and sWGS were performed to determine coding mutations and aberrant copy-number in metastatic tumors from 67 patients, 33 of which were assayed with corresponding matched primary tumors.
Results: Using Bayesian approaches, we find that cancers fit one of two patterns: canonical linear evolution (whereby the metastatic tumor arises from one or more advanced primary tumor subclones) vs. branched evolution (whereby both primary and metastatic tumors develop mutations that go on to become clonal within their respective tumors after the time of dissemination). In cases where tumors show evidence of branched evolution or small subclone dissemination, we expect that a large proportion of mutations may not be represented in both the primary and corresponding metastatic tumors. Indeed, primary-metastatic tumor pairs show substantial discordance at the genomic level, sharing only ˜30% of mutations and ˜28% of copy-number alterations on average. Furthermore, we find that metastatic tumors have decreased clonal heterogeneity, suggesting a history of selection. Indeed, we find clinically relevant mutations that are present exclusively in the primary or the corresponding recurrent metastatic tumor, as well as genes that are recurrently altered in metastatic tumors, such as amplification of SRC-1, loss of genes encoding CDK inhibitors, and alterations in JAK1/2/3.Finally, compared to the primary tumors from which they arose, metastatic tumors exhibit increased frequencies of alterations in several discrete pathways, including those involving the extracellular matrix as well as PI3K/AKT/mTOR, estrogen, and HER2 signaling.
Conclusions: The low degree of genomic concordance between primary and metastatic tumors due to evolutionary distance, as well as the presence of activating and targetable mutations specifically in metastatic tumors, suggests that there is value in comprehensively characterizing metastatic tumors to inform patient treatment and identify novel targets underlying breast cancer progression.
Citation Format: Paul MR, Pan T-C, Pant D, Belka GK, Chen Y, Shih N, Lieberman D, Morrissette JJD, Soucier-Ernst D, Clark C, Stavropoulos W, Maxwell K, Feldman M, DeMichele A, Chodosh LA. Evolutionary history and genomic landscape of metastatic breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD8-04.
Collapse
Affiliation(s)
- MR Paul
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - T-C Pan
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - D Pant
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - GK Belka
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - Y Chen
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - N Shih
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - D Lieberman
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - JJD Morrissette
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - D Soucier-Ernst
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - C Clark
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - W Stavropoulos
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - K Maxwell
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - M Feldman
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - A DeMichele
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - LA Chodosh
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
22
|
Burstein HJ, Mayer EL, DeMichele A, Harnett J, Mardekian J, McRoy L, Huang Bartlett C, Koehler M, Fahed Rimawi M. Abstract P3-11-01: Treatment patterns for young women with HR+/HER2- metastatic breast cancer in the United States in the era of CDK 4/6 inhibitors. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-11-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: NCCN guidelines recommend that premenopausal women with HR+/HER2- metastatic breast cancer (MBC) be rendered postmenopausal and then treated accordingly. After its approval in February 2015, the CDK4/6 inhibitor palbociclib (P), in combination with endocrine therapy (ET), has become a standard of care in the first-line or pretreated settings for women with HR+/HER2- MBC. Specialty pharmacy prescription data indicate that 12% of all women with HR+/HER2- MBC treated with P in the United States are younger than 50 years of age. We assessed the real world treatment patterns and outcomes before and after approval of P in women with HR+/HER2- MBC. We further sought to assess the impact of the NCCN guidelines for premenopausal women on treatment patterns and outcomes.
Methods: This retrospective cohort study utilized electronic health record (EHR) data from Flatiron Health (Fl) from 1/2012 through 4/2017 to evaluate patient characteristics and first-line ET treatment patterns among women with HR+/HER2- MBC prior to and after P approval. Menopausal status was defined by age (< 50 vs >50 yrs). Additional datasets of > 13,000 pts with MBC in the Truven Health MarketScan and Optum Clinformatics claims and Humedica EHR databases will be included to represent a more comprehensive dataset and evaluate clinical outcomes.
Results and Discussion: Initial results include 4,537 pts in the FI database who initiated a first-line ET regimen. Overall, 30% of pts < 50 yrs used P compared to 29% of women age >50. Treatment patterns for initial endocrine therapy are shown in the table.
Initial Endocrine Therapy Women <_50 yrs N (%) women > 50 yrs N(%) cohort01.2012-01.201502.2015-04.2017Absolute Change01.2012-01.201502.2015-04.2017Absolute ChangeN (%)296 (%0273 (100%) 2062 (100%)1906 (100%) ET monotx +/- LHRH296 (100%)192 (70%)-30%2062 (100%)1345 (71%)-29%TAM108 (36%)75 (27%)-9%161 (8%)78 (4%)-4%AI139 (47%)80 (29%)-18%1326 (64%)866 (45%)-19%FUL49 (17%)37 (14%)-3%575 (28%)401 (21%)-7%ET + P +/- LHRHNA81 (30%)+30%NA561 (29%)+29%% of concurrent LHRH77 (26%)92 (34%)+8%20 (1%)28 (1%)0%
Decreased use of tamoxifen as 1st line ET was observed in pts <_50 yrs over the observed time. 47% of young pts initiated endocrine based treatment with AI monotherapy in the pre-P era, consistent with the NCCN guidelines. About 26% (pre-P) and 34% (post-P) of pts ≤50 yrs initiated first ET with ovarian suppression in the analyzed treatment eras. The concurrent use of LHRH increased 8%.
Conclusions: The treatment paradigm for women with HR+/HER2- MBC has evolved over the last >5 years. Consistent with NCCN guidelines, more young pts are receiving ovarian suppression as part of initial therapy, and pts regardless of age are receiving treatment with P. There has been a related decrease in use of tamoxifen for younger pts and overall. These data illustrate rapid incorporation of palbociclib into standard care for US pts with HR+/HER2- MBC. Further treatment patterns and therapy outcome data for these groups reflecting real world use ET regimens of over 17,000 pts in the combined cohort, will be reported.
Citation Format: Burstein HJ, Mayer EL, DeMichele A, Harnett J, Mardekian J, McRoy L, Huang Bartlett C, Koehler M, Fahed Rimawi M. Treatment patterns for young women with HR+/HER2- metastatic breast cancer in the United States in the era of CDK 4/6 inhibitors [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-11-01.
Collapse
Affiliation(s)
- HJ Burstein
- Dana Farber Cancer Institute, Brigam and Women's Hospital, Harvard Medical School, Boston, MA; Perelman School of Medicine University of Pennsylvania, Philadelphia, PA; Pfizer, Inc, New York, NY; Dan L Duncan Cancer Center at Baylor College of Medicine, Houston, TX
| | - EL Mayer
- Dana Farber Cancer Institute, Brigam and Women's Hospital, Harvard Medical School, Boston, MA; Perelman School of Medicine University of Pennsylvania, Philadelphia, PA; Pfizer, Inc, New York, NY; Dan L Duncan Cancer Center at Baylor College of Medicine, Houston, TX
| | - A DeMichele
- Dana Farber Cancer Institute, Brigam and Women's Hospital, Harvard Medical School, Boston, MA; Perelman School of Medicine University of Pennsylvania, Philadelphia, PA; Pfizer, Inc, New York, NY; Dan L Duncan Cancer Center at Baylor College of Medicine, Houston, TX
| | - J Harnett
- Dana Farber Cancer Institute, Brigam and Women's Hospital, Harvard Medical School, Boston, MA; Perelman School of Medicine University of Pennsylvania, Philadelphia, PA; Pfizer, Inc, New York, NY; Dan L Duncan Cancer Center at Baylor College of Medicine, Houston, TX
| | - J Mardekian
- Dana Farber Cancer Institute, Brigam and Women's Hospital, Harvard Medical School, Boston, MA; Perelman School of Medicine University of Pennsylvania, Philadelphia, PA; Pfizer, Inc, New York, NY; Dan L Duncan Cancer Center at Baylor College of Medicine, Houston, TX
| | - L McRoy
- Dana Farber Cancer Institute, Brigam and Women's Hospital, Harvard Medical School, Boston, MA; Perelman School of Medicine University of Pennsylvania, Philadelphia, PA; Pfizer, Inc, New York, NY; Dan L Duncan Cancer Center at Baylor College of Medicine, Houston, TX
| | - C Huang Bartlett
- Dana Farber Cancer Institute, Brigam and Women's Hospital, Harvard Medical School, Boston, MA; Perelman School of Medicine University of Pennsylvania, Philadelphia, PA; Pfizer, Inc, New York, NY; Dan L Duncan Cancer Center at Baylor College of Medicine, Houston, TX
| | - M Koehler
- Dana Farber Cancer Institute, Brigam and Women's Hospital, Harvard Medical School, Boston, MA; Perelman School of Medicine University of Pennsylvania, Philadelphia, PA; Pfizer, Inc, New York, NY; Dan L Duncan Cancer Center at Baylor College of Medicine, Houston, TX
| | - M Fahed Rimawi
- Dana Farber Cancer Institute, Brigam and Women's Hospital, Harvard Medical School, Boston, MA; Perelman School of Medicine University of Pennsylvania, Philadelphia, PA; Pfizer, Inc, New York, NY; Dan L Duncan Cancer Center at Baylor College of Medicine, Houston, TX
| |
Collapse
|
23
|
Yau C, Wolf D, Brown-Swigart L, Hirst G, Sanil A, Singhrao R, Asare S, DeMichele A, Berry D, Esserman L, van 't Veer L, Nanda R, Liu M, Yee D. Abstract PD6-14: Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd6-14] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pembrolizumab (P), an anti-PD-1 immune checkpoint inhibitor, has been approved for treatment of microsatellite instability-high and mismatch repair deficient cancers. In I-SPY 2, patients were randomized to receive standard chemotherapy alone or in combination with an experimental agent. P was one of the experimental agents evaluated in HER2- patients in I-SPY 2 and graduated in the TN, HR+HER2-, and HER2- signatures. We hypothesize that a combination of two signatures predicting response to veliparib/carboplatin therapy in I-SPY 2 [MammaPrint High2 (MP2)/PARPi7-high] and reflecting DNA damage repair deficiency, may also predict response to P. In addition, we also tested 9 gene expression signatures reflecting different aspects of DNA damage and repair: FA, MMR, BER, HR, TLS, NER, NHEJ, DR, and DNA damage sensing (DDS) pathways.
Methods: Data from 249 patients (P: 69 and controls: 180) were available. Pre-treatment biopsies were assayed using Agilent gene expression arrays. All I-SPY 2 qualifying biomarker analyses follow a pre-specified analysis plan. We used logistic modeling to assess biomarker performance. A biomarker is considered a specific predictor of P response if it associates with response in the P arm but not the control arm, and if the biomarker x treatment interaction is significant (likelihood ratio test, p<0.05). This analysis is also performed adjusting for HR status as a covariate, and within receptor subsets, sample size permitting. For successful biomarkers, we use Bayesian modeling to estimate the pCR rates of 'predicted sensitive' patients in each arm. Our statistics are descriptive rather than inferential and do not adjust for multiplicities of other biomarkers outside this study.
Results: MP2 status associates with pCR in P (OR=7.7; p=0.00021), but also to a lesser extent in the control arm (OR=2.4:p=0.045), with an OR ratio of 3.3 which trends toward significance, even after adjusting for HR status (LR p=0.083). A majority of TN patients are MP2; and TN/MP2 patients have an estimated pCR rate of 67% in P (vs. 23% in control). Although only ~30% of HR+HER2- patients were MP2, their estimated pCR rate in P is 61%, compared to 29% in unselected HR+/HER2- patients. PARPi7 predicted response in the P arm only in the HR+HER2- group (LR p= 0.025), but not in the population as a whole or the TN subtype. Combining MP2 and PARPi7 into MP2/PARPi7-high did not improve performance over MP2 as a single biomarker. Of the 9 DDR pathway signatures tested, both BER and DDS associate with pCR in P, but only DDS (which includes ATM, ATR, CHEK1-2) associates with pCR in the P arm (LR p=0.00029), and not the control arm (LR p=0.53), with a significant interaction with treatment (LR p=0.0064) that retains significance in a model adjusting for HR status. When dichotomized to optimize the biomarker x treatment interaction, the estimated pCR rate is 75% in P vs 18% in control, in the DDS+ subset.
Conclusion: In this small study, MP2 status and a DNA damage sensing pathway but not the PARPi7 or other repair pathways show promise as predictive biomarkers for immune checkpoint inhibition therapy in breast cancer.
Citation Format: Yau C, Wolf D, Brown-Swigart L, Hirst G, Sanil A, Singhrao R, I-SPY 2 TRIAL Investigators, Asare S, DeMichele A, Berry D, Esserman L, van 't Veer L, Nanda R, Liu M, Yee D. Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD6-14.
Collapse
Affiliation(s)
- C Yau
- University of California, San Francisco; Berry Consultants, LLC; QuantumLeap Healthcare Collective; University of Penssylvania; University of Chicago; Mayo Clinic; University of Minnesota
| | - D Wolf
- University of California, San Francisco; Berry Consultants, LLC; QuantumLeap Healthcare Collective; University of Penssylvania; University of Chicago; Mayo Clinic; University of Minnesota
| | - L Brown-Swigart
- University of California, San Francisco; Berry Consultants, LLC; QuantumLeap Healthcare Collective; University of Penssylvania; University of Chicago; Mayo Clinic; University of Minnesota
| | - G Hirst
- University of California, San Francisco; Berry Consultants, LLC; QuantumLeap Healthcare Collective; University of Penssylvania; University of Chicago; Mayo Clinic; University of Minnesota
| | - A Sanil
- University of California, San Francisco; Berry Consultants, LLC; QuantumLeap Healthcare Collective; University of Penssylvania; University of Chicago; Mayo Clinic; University of Minnesota
| | - R Singhrao
- University of California, San Francisco; Berry Consultants, LLC; QuantumLeap Healthcare Collective; University of Penssylvania; University of Chicago; Mayo Clinic; University of Minnesota
| | - S Asare
- University of California, San Francisco; Berry Consultants, LLC; QuantumLeap Healthcare Collective; University of Penssylvania; University of Chicago; Mayo Clinic; University of Minnesota
| | - A DeMichele
- University of California, San Francisco; Berry Consultants, LLC; QuantumLeap Healthcare Collective; University of Penssylvania; University of Chicago; Mayo Clinic; University of Minnesota
| | - D Berry
- University of California, San Francisco; Berry Consultants, LLC; QuantumLeap Healthcare Collective; University of Penssylvania; University of Chicago; Mayo Clinic; University of Minnesota
| | - L Esserman
- University of California, San Francisco; Berry Consultants, LLC; QuantumLeap Healthcare Collective; University of Penssylvania; University of Chicago; Mayo Clinic; University of Minnesota
| | - L van 't Veer
- University of California, San Francisco; Berry Consultants, LLC; QuantumLeap Healthcare Collective; University of Penssylvania; University of Chicago; Mayo Clinic; University of Minnesota
| | - R Nanda
- University of California, San Francisco; Berry Consultants, LLC; QuantumLeap Healthcare Collective; University of Penssylvania; University of Chicago; Mayo Clinic; University of Minnesota
| | - M Liu
- University of California, San Francisco; Berry Consultants, LLC; QuantumLeap Healthcare Collective; University of Penssylvania; University of Chicago; Mayo Clinic; University of Minnesota
| | - D Yee
- University of California, San Francisco; Berry Consultants, LLC; QuantumLeap Healthcare Collective; University of Penssylvania; University of Chicago; Mayo Clinic; University of Minnesota
| | | |
Collapse
|
24
|
Yee D, Paoloni M, van't Veer L, Sanil A, Yau C, Forero A, Chien AJ, Wallace AM, Moulder S, Albain KS, Kaplan HG, Elias AD, Haley BB, Boughey JC, Kemmer KA, Korde LA, Isaacs C, Minton S, Nanda R, DeMichele A, Lang JE, Buxton MB, Hylton NM, Symmans WF, Lyandres J, Hogarth M, Perlmutter J, Esserman LJ, Berry DA. Abstract P6-11-04: The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-11-04] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes to evaluate novel agents when added to standard neoadjuvant therapy for women with high-risk stage II/III breast cancer - investigational agent(I) +paclitaxel(T) qwk, doxorubicin & cyclophosphamide(AC) q2-3 wk x 4 vs. T/AC (control arm). The primary endpoint is pathologic complete response (pCR) at surgery. The goal is to identify/graduate regimens that have ≥85% Bayesian predictive probability of success (statistical significance) in a 300-patient phase 3 neoadjuvant trial defined by hormone-receptor (HR) & HER2 status & MammaPrint (MP). Regimens may also leave the trial for futility (< 10% probability of success) or following accrual of maximum sample size (10%< probability of success <85%). We report the results for experimental arm Ganitumab, a type I insulin-like growth factor receptor (IGF1R) inhibitor. IGF1R inhibitors are known to induce insulin resistance and all patients assigned to Ganitumab received metformin.
Methods: Women with tumors ≥2.5cm were eligible for screening. MP low/HR+ and HER2+ tumors were ineligible for randomization. Hemoglobin A1C≥ 8.0% were ineligible. MRI scans (baseline, 3 cycles after start of therapy, at completion of weekly T and prior to surgery) were used in a longitudinal statistical model to improve the efficiency of adaptive randomization. Ganitumab was given at 12mg/kg q2 weeks and metformin at 850mg PO BID, while receiving ganitumab. Analysis was intention to treat with patients who switched to non-protocol therapy counted as non-pCRs. Ganitumab/metformin was open only to HER2- patients, and eligible for graduation in 3 of 10 pre-defined signatures: HER2-, HR+HER2- and HR-HER2-.
Results: Ganitumab/metformin did not meet the criteria for graduation in the 3 signatures tested. When the maximum sample size was reached, accrual to this arm stopped. Ganitumab/metformin was assigned to 106 patients; there were 128 controls. We report probabilities of superiority for Ganitumab/metformin over control and Bayesian predictive probabilities of success in a neoadjuvant phase 3 trial equally randomized between Ganitumab/metformin and control, for each of the 3 biomarker signatures, using the final pathological response data from all patients. Safety data will be presented.
SignatureEstimated pCR Rate (95% probability interval)Probability Ganitumab/ Metformin Is Superior to ControlPredictive Probability of Success in Phase 3 Ganitumab/ Metformin N = 106Control N = 128 All HER2-22% (13%-31%)16% (10%-23%)89%33%HR+/HER2-14% (4%-24%)12% (4%-19%)66%21%HR-/HER2-32% (17%-46%)21% (11%-32%)91%51%
Conclusion: The I-SPY 2 adaptive randomization study estimates the probability that investigational regimens will be successful in a phase 3 neoadjuvant trial. The value of I-SPY 2 is to give insight about the performance of an investigational agent's likelihood of achieving pCR. For Ganitumab/metformin, no subtype came close to the efficacy threshold of 85% likelihood of success in phase 3, and this regimen does not appear to impact upfront reduction of tumor burden. Our data do not support its continued development for the neoadjuvant treatment of breast cancer.
Citation Format: Yee D, Paoloni M, van't Veer L, Sanil A, Yau C, Forero A, Chien AJ, Wallace AM, Moulder S, Albain KS, Kaplan HG, Elias AD, Haley BB, Boughey JC, Kemmer KA, Korde LA, Isaacs C, Minton S, Nanda R, DeMichele A, Lang JE, Buxton MB, Hylton NM, Symmans WF, Lyandres J, Hogarth M, Perlmutter J, Esserman LJ, Berry DA. The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-11-04.
Collapse
Affiliation(s)
- D Yee
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - M Paoloni
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - L van't Veer
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - A Sanil
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - C Yau
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - A Forero
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - AJ Chien
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - AM Wallace
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - S Moulder
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - KS Albain
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - HG Kaplan
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - AD Elias
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - BB Haley
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - JC Boughey
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - KA Kemmer
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - LA Korde
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - C Isaacs
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - S Minton
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - R Nanda
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - A DeMichele
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - JE Lang
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - MB Buxton
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - NM Hylton
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - WF Symmans
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - J Lyandres
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - M Hogarth
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - J Perlmutter
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - LJ Esserman
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - DA Berry
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| |
Collapse
|
25
|
O'Shaughnessy J, DeMichele A, Ma C, Richards P, Yardley DA, Wright G, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo H. Abstract P4-22-04: A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Systemic inflammation is associated with poor prognosis in pts with ABC. The JAK/STAT pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. We evaluated the efficacy and safety of RUX, a JAK1/JAK2 inhibitor, plus CAPE in pts with HER2-negative ABC and high systemic inflammation defined by the modified Glasgow Prognostic Score (mGPS). Methods: In this double-blind phase 2 trial, pts were randomized 1:1 to 21 day cycles of RUX+CAPE or PBO+CAPE: RUX 15 mg or PBO PO BID for 21 d; CAPE 1000 mg/m2 PO BID for 14 d. Key inclusion criteria were systemic inflammation by mGPS of 1 or 2 (ie, CRP >10 mg/L), ECOG performance status ≤2, ≤2 prior chemotherapy regimens, and no prior CAPE. The primary endpoint was overall survival (OS); key secondary endpoints were progression-free survival (PFS), objective response rate (ORR; complete [CR] + partial response [PR]) per RECIST v1.1, clinical benefit rate (CBR; CR + PR + stable disease for ≥6 mo), duration of response, and safety. Treatment differences in OS and PFS were analyzed by the log-rank test; HRs and CIs were analyzed by the Cox proportional hazards model. Results: Baseline characteristics were similar between pts randomized to RUX+CAPE (n=76) vs PBO+CAPE (n=73): mGPS status (1, 82.9% vs 83.6%), hormone receptor (HR) status (positive, 67.1% vs 63.0%), and number of prior chemotherapy regimens for ABC (0, 50.0% vs 50.7%; 1, 38.2% vs 34.2%; 2, 9.2% vs 13.7%). Median treatment durations were 85 d with RUX in the RUX+CAPE group and 65 d with PBO in the PBO+CAPE group. Median OS was 11.2 mo with RUX+CAPE vs 10.9 mo with PBO+CAPE (HR, 0.932; 95% CI, 0.59–1.46; P=0.762). Median OS was 6.1 mo with RUX+CAPE vs 5.5 mo with PBO+CAPE in HR-negative pts and 11.7 mo and 12.2 mo in HR-positive pts. Median PFS was 4.5 mo with RUX+CAPE and 2.5 mo with PBO+CAPE (HR, 0.737; 95% CI, 0.49–1.12; P=0.151). Median PFS was 2.1 mo with RUX+CAPE vs 2.2 mo with PBO+CAPE in HR-negative pts and 6.1 mo and 4.1 mo in HR-positive pts. ORRs were 28.9% and 13.7% (P=0.024) in the RUX+CAPE and PBO+CAPE arms, respectively. The CBRs were 13.2% and 6.8%, respectively (P=0.278). Worsening of hematologic toxicity was higher and rates of grade 3/4 palmar-plantar erythrodysethesia (PPE) were lower (1.4% vs 12.7%, respectively) with RUX+CAPE (Table).
Safety RUX+CAPE (n=71)PBO+CAPE (n=71)%All-GradeGrade 3/4All-GradeGrade 3/4Nonhematologic Adverse Event*Fatigue56.35.643.74.2Nausea54.98.549.35.6Diarrhea47.98.526.82.8PPE46.51.438.012.7Vomiting38.05.629.64.2Hypokalemia15.58.57.02.8Worsening of Hematologic Toxicity†Anemia80.323.956.37.0Lymphopenia40.815.545.112.7Neutropenia39.411.322.52.8Thrombocytopenia39.411.315.51.4*Most common all-grade (≥35%) or grade 3/4 (≥5%) events in the RUX+CAPE arm (safety group). †Laboratory abnormalities.
Conclusion: These data support the prognostic capabilities of the mGPS. The addition of RUX to CAPE for pts with ABC and high systemic inflammation was associated with an improved ORR compared with PBO+CAPE, but did not improve OS or PFS.
Citation Format: O'Shaughnessy J, DeMichele A, Ma C, Richards P, Yardley DA, Wright G, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo H. A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-04.
Collapse
Affiliation(s)
- J O'Shaughnessy
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - A DeMichele
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - C Ma
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - P Richards
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - DA Yardley
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - G Wright
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - K Kalinsky
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - R Steis
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - S Diab
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - G Kennealey
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - R Geschwindt
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - W Jiang
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - H Rugo
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| |
Collapse
|
26
|
Forero A, Yee D, Buxton MB, Symmans WF, Chien AJ, Boughey JC, Elias AD, DeMichele A, Moulder S, Minton S, Kaplan HG, Albain KS, Wallace AM, Haley BB, Isaacs C, Korde LA, Nanda R, Lang JE, Kemmer KA, Hylton NM, Paoloni M, van't Veer L, Lyandres J, Perlmutter J, Hogarth M, Yau C, Sanil A, Berry DA, Esserman LJ. Abstract P6-11-02: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-11-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Pathologic complete response(pCR) after neoadjuvant therapy is an established prognostic biomarker for high-risk breast cancer(BC). Improving pCR rates may identify new therapies that improve survival. I-SPY 2 uses response-adaptive randomization within biomarker subtypes to evaluate novel agents when added to standard neoadjuvant therapy for women with high-risk stage II/III breast cancer; the goal is to identify regimens that have ≥85% Bayesian predictive probability of success (statistical significance) in a 300-patient phase 3 neoadjuvant trial defined by hormone-receptor (HR), HER2 status and MammaPrint (MP). We report the results for Ganetespib, a selective inhibitor of Hsp90 that induces the degradation/deactivation of key drivers of tumor initiation, progression, angiogenesis, and metastasis.Ganetespib + taxanes previously have resulted in a superior therapeutic response compared to monotherapy in multiple solid tumor models including BC.
Methods:Women with tumors ≥2.5cm were eligible for screening and participation. MP low/HR+ tumors were ineligible for randomization. QTcF >470msec and HbA1C >8.0% were ineligible. MRI scans (baseline, +3 cycles, following weekly paclitaxel, T, and pre-surgery) were used in a longitudinal statistical model to improve the efficiency of adaptive randomization. Ganetespib was given with weekly T at 150 mg/m2 IV weekly (3 weeks on, 1 off). Patients were premedicated (dexamethasone 10mg and diphenhydramine HCl 25-50 mg, or therapeutic equivalents). Analysis was intention to treat with patients who switched to non-protocol therapy counted as non-pCRs. The Ganetespib regimen was open only to HER2- patients, and eligible for graduation in 3 of 10 pre-defined signatures: HER2-, HR+/HER2- and HR-/HER2-.
Results:Ganetespib did not meet the criteria for graduation in the 3 signatures tested. When the maximum sample size was reached, accrual stopped. Ganetespib was assigned to 93 patients; there were 140 controls. We report probabilities of superiority for Ganetespib over control and Bayesian predictive probabilities of success in a neoadjuvant phase 3 trial equally randomized between Ganetespib and control, for the 3 biomarker signatures, using the final pCR data from all patients. Safety data will be presented.
SignatureEstimated pCR Rate (95% probability interval)Probability Ganetespib Is Superior to ControlPredictive Probability of Ganetespib Success in a Phase 3 Trial Ganetespib N = 93Control N = 140 All HER2-26% (16%-37%)18% (8%-28%)91%47%HR+/HER2-15% (4%-27%)14% (4%-24%)60%19%HR-/HER2-38% (23%-53%)22% (9%-35%)96%72%
Conclusion:The I-SPY 2 adaptive randomization model efficiently evaluates investigational agents in the setting of neoadjuvant BC. The value of I-SPY 2 is that it provides insight as to the regimen's likelihood of success in a phase 3 neoadjuvant study. Although no signature reached the efficacy threshold of 85% likelihood of success in phase 3, we observed the most impact in HR-/HER2- patients, with a 16% improvement in pCR rate. While our data do not support the continued development of Ganetespib alone for neoadjuvant BC, combinations with Ganetespib, which could potentiate its effect, may be worth pursuing in I-SPY 2 or similar trials.
Citation Format: Forero A, Yee D, Buxton MB, Symmans WF, Chien AJ, Boughey JC, Elias AD, DeMichele A, Moulder S, Minton S, Kaplan HG, Albain KS, Wallace AM, Haley BB, Isaacs C, Korde LA, Nanda R, Lang JE, Kemmer KA, Hylton NM, Paoloni M, van't Veer L, Lyandres J, Perlmutter J, Hogarth M, Yau C, Sanil A, Berry DA, Esserman LJ. Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-11-02.
Collapse
Affiliation(s)
- A Forero
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - D Yee
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - MB Buxton
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - WF Symmans
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - AJ Chien
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - JC Boughey
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - AD Elias
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - A DeMichele
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - S Moulder
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - S Minton
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - HG Kaplan
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - KS Albain
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - AM Wallace
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - BB Haley
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - C Isaacs
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - LA Korde
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - R Nanda
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - JE Lang
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - KA Kemmer
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - NM Hylton
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - M Paoloni
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - L van't Veer
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - J Lyandres
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - J Perlmutter
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - M Hogarth
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - C Yau
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - A Sanil
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - DA Berry
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - LJ Esserman
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| |
Collapse
|
27
|
Bardia A, Hurvitz S, Yardley DA, Zelnak A, DeMichele A, Clark AS, Warsi G, Small T, Tucci C, Moulder S. Abstract OT2-01-05: TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2– advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot2-01-05] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: There is extensive crosstalk between the cyclin D–CDK4/6–inhibitor of CDK4–retinoblastoma and phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathways at the G1/S cell-cycle checkpoint. Both pathways are frequently dysregulated in hormone receptor-positive (HR+) breast cancer and have been associated with endocrine therapy (ET) resistance. CDK4/6 and PI3K/mTOR inhibitors have demonstrated clinical activity in combination with ET. Although CDK4/6 inhibitors combined with ET significantly improve progression-free survival (PFS) in ABC, disease progression eventually occurs, highlighting the need for effective treatment options following doublet therapy. Ribociclib (LEE011; CDK4/6 inhibitor; 3-weeks-on/1-week-off) + EVE (mTOR inhibitor) + EXE triplet therapy has shown preliminary clinical activity in heavily pretreated HR+, human epidermal growth factor receptor 2-negative (HER2–) ABC including patients (pts) with prior exposure to CDK4/6 inhibitors, suggesting this combination may restore sensitivity to CDK4/6 inhibitor-based therapy.
Trial design and objectives: TRINITI-1 (NCT02732119) is a US-based, phase I/II, single arm, open-label study of ribociclib (continuous daily dosing) + EVE (2.5 mg/day) + EXE (25 mg/day) in men and postmenopausal women with HR+, HER2– ABC refractory to ≥1 line of ET. Phase I dose escalation consists of 2 ribociclib dose-level cohorts (250 and 300 mg/day), followed by a Simon Two-Stage phase II trial in pts with disease progression on prior CDK4/6 inhibitor-based therapy. No more than 3 lines of therapy for ABC, including ≤1 prior chemotherapy regimen, are permitted. Previous EXE treatment of >28 days for metastatic disease, prior mTOR inhibitors, and progression on >1 CDK4/6 inhibitor are prohibited. All pts in phase II must have progressed on a CDK4/6 inhibitor as the last regimen before study entry. Additional eligibility criteria include measurable disease or lytic/mixed bone lesions and Eastern Cooperative Oncology Group performance status of ≤1. Exclusion criteria include visceral crisis, unstable CNS metastases, and clinically significant heart disease. Phase I primary objective: maximum tolerated dose and/or recommended phase II dose of the triplet combination. Phase II primary objective: clinical benefit rate (CBR) at 24 weeks (0.1 significance level, 80% power to test CBR ≤15% against CBR ≥30%) with centrally-assessed PFS as a key secondary objective. Other secondary objectives include preliminary antitumor activity (phase I), safety and pharmacokinetics (phase I/II), and overall response rate, overall survival, and duration of overall response (phase II). Tumor assessments (RECIST v1.1) will be performed every 8 weeks for the first 12 months, and every 12 weeks thereafter until disease progression. Exploratory analyses include biomarkers potentially predictive of response and mechanisms of resistance.
Target accrual: Approximately 52 pts at ∼30 sites; 3–6 pts per cohort in phase I, an initial 19 in phase II with another 20 enrolled upon demonstration of clinical benefit in ≥4 pts.
Citation Format: Bardia A, Hurvitz S, Yardley DA, Zelnak A, DeMichele A, Clark AS, Warsi G, Small T, Tucci C, Moulder S. TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2– advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT2-01-05.
Collapse
Affiliation(s)
- A Bardia
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of California, Los Angeles, Santa Monica, CA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Northside Hospital, Atlanta, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Hurvitz
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of California, Los Angeles, Santa Monica, CA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Northside Hospital, Atlanta, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - DA Yardley
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of California, Los Angeles, Santa Monica, CA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Northside Hospital, Atlanta, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A Zelnak
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of California, Los Angeles, Santa Monica, CA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Northside Hospital, Atlanta, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A DeMichele
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of California, Los Angeles, Santa Monica, CA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Northside Hospital, Atlanta, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - AS Clark
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of California, Los Angeles, Santa Monica, CA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Northside Hospital, Atlanta, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - G Warsi
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of California, Los Angeles, Santa Monica, CA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Northside Hospital, Atlanta, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - T Small
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of California, Los Angeles, Santa Monica, CA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Northside Hospital, Atlanta, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - C Tucci
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of California, Los Angeles, Santa Monica, CA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Northside Hospital, Atlanta, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Moulder
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of California, Los Angeles, Santa Monica, CA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Northside Hospital, Atlanta, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
28
|
Gallagher RI, Yau C, Wolf DM, Dong T, Hirst G, Brown-Swigart L, Buxton M, DeMichele A, van't Veer L, Yee D, Paoloni M, Esserman L, Berry D, Park J, Petricoin EF, Wulfkuhle JD. Abstract P3-05-02: Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-05-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: We have previously described that TNBC patients whose tumors have both HER2 Y1248 phosphorylation (pHER2) “high” and phospho-EGFR Y1173 (pEGFR) “high” have increased response (pCR) to neratinib in the I-SPY2 TRIAL. We hypothesize that the paradoxical finding of a response prediction signature comprised of HER2 activation in a HER2 IHC/FISH-negative population means there must be a ligand-driven biochemical event responsible for the HER2 phosphorylation because HER2 mutations were also not found to be significant. Exploratory analysis of additional cellular signaling events and protein expression levels in pre-treatment, LCM-purified tumor epithelium by reverse phase protein microarray (RPPA) included semi-quantitative measurement of total levels of estrogen receptor alpha (ERα), which has been previously shown to be able to act as a membrane non-genomic signaling molecule through direct interaction with various tyrosine kinases including EGFR and HER2. Since ERα has been previously shown to act as a ligand and co-stimulate (activate) HER2 and EGFR when present at low levels, we investigated whether or not RPPA-measured ERα levels in the TNBC cohort analyzed to date were higher in tumors with both pHER2 “high” and pEGFR “high” levels and thus provide evidence explaining how HER2-EGFR activation is occurring in TNBC.
Methods: Using RPPA analysis, we measured 118 analytes in lysates of LCM tumor epithelium obtained from the pre-treatment biopsy samples of 86 TNBC (Allred=0) patients in the I-SPY2 TRIAL analyzed to date. Cutpoints for pEGFR and pHER2 were determined previously by ROC analysis for pCR correlation in the neratinib treated TNBC population, and used here to dichotomize the pHER2 and pEGFR data in the larger TNBC population. Wilcoxon Rank Sum testing was performed using the continuous variable total ERα data and compared the TNBC that were both pHER2 and pEGFR “high” (N=39) to the rest of the TNBC population (N=47). Total ERα values were then divided into “high” and “low” groups based on the TNBC population median value in order to determine frequency/percentages within each class. Our study is exploratory with no claims for generalizability of the data, and calculations are descriptive (e.g. p-values are measures of distance with no inferential content).
Results: Total ERα values were obtained in 84/86 TNBC tumors analyzed. Total levels of ERα were higher (p< 0.006) in TNBC tumors with pHER2 and pEGFR “high” levels. 68% (26/38) of tumors in the pHER2 and pEGFR “high” group had ERα levels above the population median compared to 35% (16/46) in the rest of the TNBC population.
Conclusion: Our exploratory analysis reveals that ERα levels are significantly higher in TNBC with pHER2 and pEGFR activation and may be behaving as a direct signaling ligand in TNBC and driving HER2-EGFR signaling. This ERα-pHER2/pEGFR association was missed by current ER and HER2 clinical laboratory testing techniques, and if validated in larger independent study sets could suggest that utilization of new protein-based techniques defining ER more quantitatively could be helpful to understand tumor biology and therapeutic response prediction, especially in the context of TNBC that are ostensibly ER negative.
Citation Format: Gallagher RI, Yau C, Wolf DM, Dong T, Hirst G, Brown-Swigart L, ISPY-2 TRIAL Investigators, Buxton M, DeMichele A, van't Veer L, Yee D, Paoloni M, Esserman L, Berry D, Park J, Petricoin EF, Wulfkuhle JD. Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-05-02.
Collapse
Affiliation(s)
- RI Gallagher
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - C Yau
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - DM Wolf
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - T Dong
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - G Hirst
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - L Brown-Swigart
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - M Buxton
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - A DeMichele
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - L van't Veer
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - D Yee
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - M Paoloni
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - L Esserman
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - D Berry
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - J Park
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - EF Petricoin
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - JD Wulfkuhle
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | | |
Collapse
|
29
|
Paoloni M, Lyandres J, Buxton MB, Berry DA, Esserman LJ, DeMichele A, Yee D. Abstract P2-11-02: A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-11-02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes to evaluate a series of investigational agents or regimens when added to standard neoadjuvant therapy for women with high-risk stage II/III breast cancer - investigational agent (I) +paclitaxel (T) qwk, doxorubicin & cyclophosphamide (AC) q2-3 wk x 4 vs. T+/-HP/AC (control arm(s)). Although the primary endpoint is pathologic complete response (pCR) at surgery, a key secondary aim is to evaluate the toxicity profiles of these investigational agents. Distinct aspects of safety monitoring in a platform trial, as well as the specificities of safety management in a potentially curative population make the experiences from I-SPY 2 valuable to the community.
Methods: Inclusion and exclusion criteria are uniformly applied to all women in I-SPY 2. When a new investigational agent/regimen is planned for the trial, agent specific laboratory/hematologic limits or additional required tests are added, as needed. Eligibility criteria remain in the trial for its duration and apply to all investigational and control arms. Laboratory and adverse event data are collected and monitored in real time. The lead investigator of the investigational agent/regimen who chaperones a specific agent/regimen through the trial (“Agent Chaperone”), Medical Monitor, I-SPY 2 Agents Committee, CRO safety group, and an active DSMB that meets monthly oversee the management of toxicities within each investigational agent/regimen of the trial. Toxicity profiles for an investigational agent/regimen are compared to their relevant control. Safety analyses are intention to treat.
Results: From March 2010-May 2016, eleven (11) investigational agents/regimens have opened (and 6 have completed evaluation) and 973 women have been randomized. These agents/regimens span a variety of mechanisms of action including targeted therapies such as small molecule inhibitors and antibodies, as well as immunotherapies. Additions to the trial's eligibility criteria have been made with new investigational arms. Adverse events of special interest have been monitored for each investigational arm and specific toxicities treated uniformly when applicable. A risk-based monitoring plan has been implemented that focuses on the collection and review of the trial's most critical data elements including serious adverse events and drug specific safety issues, allowing for a more efficient and focused effort. Safety issues have been quickly addressed and requirements updated, when needed, given the importance of limiting (or avoiding) long-term safety complications within this neoadjuvant patient population. Accrual to the trial has (been) maintained over time and the safety of trial participants has been well managed.
Conclusion: A platform trial requires an evolving, and focused safety-monitoring process that adapts as new investigational agents are included. I-SPY 2's infrastructure and team science approach has created a system to manage patients across multiple arms with different risk profiles. These practices will support the safe evaluation of additional new combinations and regimens and serves as a guide for safety management within standing platform trials.
Citation Format: Paoloni M, Lyandres J, Buxton MB, Berry DA, Esserman LJ, DeMichele A, Yee D. A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-11-02.
Collapse
Affiliation(s)
- M Paoloni
- QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; University of Minnesota, Minneapolis, MN
| | - J Lyandres
- QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; University of Minnesota, Minneapolis, MN
| | - MB Buxton
- QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; University of Minnesota, Minneapolis, MN
| | - DA Berry
- QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; University of Minnesota, Minneapolis, MN
| | - LJ Esserman
- QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; University of Minnesota, Minneapolis, MN
| | - A DeMichele
- QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; University of Minnesota, Minneapolis, MN
| | - D Yee
- QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; University of Minnesota, Minneapolis, MN
| |
Collapse
|
30
|
Tchou J, Zhang PJ, Levine BL, Zhao Y, Matro J, DeMichele A, Amy C, Schuchter L, Plesa G, Vonderheide RH, June C. Abstract P6-10-08: Preliminary results of a first in human Phase 1 clinical trial to demonstrate safety and feasibility of chimeric antigen receptor T (CART) cells directed against c-Met in the treatment of breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-10-08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- J Tchou
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - PJ Zhang
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - BL Levine
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Y Zhao
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - J Matro
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - A DeMichele
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - C Amy
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - L Schuchter
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - G Plesa
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - RH Vonderheide
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - C June
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| |
Collapse
|
31
|
Shah M, Jensen R, Yau C, Straehley I, Berry DA, DeMichele A, Buxton MB, Hylton NM, Perlmutter J, Symmans WF, Tripathy D, Yee D, Wallace A, Kaplan HG, Clark A, Chien AJ, Esserman LJ, Melisko ME. Abstract P5-11-18: Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-11-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Patients (pts) receiving chemotherapy for breast cancer experience toxicities impacting short and long-term quality of life (QOL). Within I-SPY 2, a trial adaptively randomizing stage II/III breast cancer pts to neoadjuvant chemotherapy +/- an investigational agent, we are collecting pt reported outcome (PRO) data to understand the impact of investigational agents on QOL. This PRO sub-study provides a unique opportunity to study QOL longitudinally and explore how pt and tumor characteristics, exposure to investigational therapies, and surgical outcome impact QOL.
Methods
Pts enrolled in this trial receive paclitaxel (T) +/- an investigational agent for 12 weeks followed by 4 cycles of doxorubicin and cyclophosphamide (AC). Surveys include the EORTC QLQ-C30 and BR-23, and PROMIS measures for QOL metrics including but not limited to physical function (PF), anxiety, and depression. Surveys are administered pre-chemotherapy to 2 years post-surgery. PF data from the EORTC and PROMIS instruments was analyzed for 238 pts at 5 sites (UCSF, UCSD, U of Pennsylvania, U of Minnesota, and Swedish Cancer Center). 48 pts completed baseline, inter-regimen (between T and AC), pre-operative and post-surgery surveys. Of the 48 pts 32 completed a 6-month follow up (FUP) and 31 completed a 1-year FUP survey. A linear mixed effect model, adjusting for HER2 status and treatment type was used to evaluate changes in PF over time. Sample size is small and statistics are descriptive rather than inferential.
Results
Median age of pts in this analysis was 50 (range 27-72).
Table 1 shows PROMIS & EORTC PF scores in this cohort.Time Point PROMISEORTC nMeanSEMeanSEPre-TreatmentAll4852.51.092.02.0 HER2+1553.51.594.12.2 HER2-3352.11.391.12.8Inter-RegimenAll4845.51.282.22.7 HER2+1548.62.384.44.2 HER2-3344.11.381.23.4Pre-SurgeryAll4843.91.179.42.3 HER2+1545.12.275.34.1 HER2-3343.41.381.32.86-Month FUPAll3248.11.487.41.9 HER2+1247.52.285.03.3 HER2-2048.41.888.92.41 Year FUPAll3148.91.488.43.1 HER2+949.12.988.95.4 HER2-2248.81.788.33.8
At baseline, mean PROMIS PF scores were higher than the US average (mean = 50) but declined as expected throughout treatment. HER2+ patients experienced a similar degree of recovery as HER2- pts post-surgery despite adjuvant treatment with Herceptin. Analysis of post-operative PROMIS PF indicated an average score within the U.S. general population (mean =50) but did not return to higher functioning seen at baseline levels (mean 52.5, p-value < 0.05). Analysis of the EORTC PF sub-scale demonstrated a similar trend; however, the baseline and post-operative difference was not significant (p-value=0.15 for both FUP). Finding supports PROMIS PF ability to measure high functioning cancer patients.
Conclusions: Among a subset of pts who completed all surveys in the I-SPY 2 QOL substudy, PF did not return to baseline at 6-12 months post-operatively. Through transition to an electronic platform of data collection we hope to improve compliance with survey completion. We continue to analyze other QOL measures and plan to correlate QOL data with treatment arm, adverse events, comorbidities, and response to neoadjuvant treatment.
Citation Format: Shah M, Jensen R, Yau C, Straehley I, Berry DA, DeMichele A, Buxton MB, Hylton NM, Perlmutter J, Symmans WF, Tripathy D, Yee D, Wallace A, Kaplan HG, Clark A, Chien AJ, I-SPY 2 Investigators, Esserman LJ, Melisko ME. Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-11-18.
Collapse
Affiliation(s)
- M Shah
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - R Jensen
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - C Yau
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - I Straehley
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - DA Berry
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - A DeMichele
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - MB Buxton
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - NM Hylton
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - J Perlmutter
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - WF Symmans
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - D Tripathy
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - D Yee
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - A Wallace
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - HG Kaplan
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - A Clark
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - AJ Chien
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - LJ Esserman
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | - ME Melisko
- University of California, San Francisco, San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Berry Consultants, Austin, TX; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN; University of California, San Diego, San Diego, CA; Swedish Meidcal Center, Seattle, WA; QuantumLeap Healthcare Collaborative, San Francisco, CA
| | | |
Collapse
|
32
|
Meric-Bernstam F, Tannir N, Harding J, Voss M, Mier J, DeMichele A, Munster P, Patel M, Iliopoulos O, Owonikoko T, Whiting S, Orford K, Bennett M, Carvajal R, McKay R, Fan A, Telli M, Infante J. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC). Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32626-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
33
|
Lynch MC, Mankoff D, Bradbury AR, Domchek S, Glick JH, Matro J, DeMichele A, Clark AS. Abstract P6-01-02: Flourine-18-fluorodeoxyglucose positron emission tomography for the evaluation of response to therapy in bone-dominant metastatic breast cancer: Examination in patients enrolled on UPCC 17113. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Response of bone-only (BO) and bone-dominant (BD) metastatic breast cancer (mBC) to therapy is difficult to assess by conventional imaging. UPCC 17113 is a single institution prospective cohort study evaluating FDG PET at early and conventional follow up intervals, 4 and 12 weeks respectively, in patients with hormone receptor (HR) positive mBC receiving endocrine therapy. The objective of this study is to assess the relationship between changes relative to baseline in standard uptake values (SUV) of specific bone lesions and progression free survival (PFS). We will also explore change in SUV as it relates to overall survival (OS) and skeletal related events (SRE). We present interim results.
Methods: Enrolled patients were ≥18 years with biopsy proven or documented clinically obvious HR-positive BD/BO mBC due to start new endocrine therapy. Any line endocrine therapy was allowed. FDG PET was performed at baseline, 4 and 12 weeks after initiation of new therapy. SUVmax for the 5 most metabolically active osseous lesions, excluding sites previously treated by radiation or surgery, were recorded at baseline, 4- and 12- week time-points. Average index lesion SUVmax (sum SUVmax/#lesions) and % change from baseline were calculated. Decline of ≥30% from baseline was defined as significant.
Results: As of 6/1/2015, 11 patients were enrolled. All patients have completed the 4-week scan and 8 have completed the 12-week scan. Five and 6 out of the 11 patients had BO and BD HR-positive mBC respectively. Detectable changes in SUV from baseline were noted in all patients at both 4 and 12 weeks, with a 37% overall decline in average index lesion SUVmax at 4 weeks. 8 of 11 patients had a ≥30% decline, in SUV at 4 weeks averaging 46%. Five of the 6 patients in this group who completed the 12-week scan had a sustained decline averaging 50% from the baseline. Of note, the average decline between 4 and 12 weeks in this group was only 8%. Despite having an overall decline from baseline of 44%, the sixth patient in this group had an increase between 4 and 12 weeks of 22%. Three of the 11 patients had a <30% decline at 4 weeks with an average decline of 12%. Of the two patients in this group with 12 week scans, both had average increase of 25% from 4 weeks to 12 weeks, and an average overall increase from baseline of 12%.
Conclusions: There are detectable changes in FDG SUV of osseous lesions at 4 and 12 weeks following initiation of endocrine therapy in patients with BO or BD HR positive mBC. Our interim results demonstrate the emergence of 3 groups of patients: (1) those who have a <30% decline at 4 weeks and increase of SUV at 12 weeks, (2) those who have a ≥30% decline in SUV at 4 weeks with sustained decline at 12 weeks, and (3) those who have a ≥30% reduction in SUV at 4 weeks but who do not have a sustained decline at 12 weeks. These interim results suggest that early FDG PET/CT may provide information on mBC response to endocrine therapy and insight into timing of response and progression. As more patients are enrolled and complete the studies, clearer patterns will emerge which will be correlated with PFS, OS and SRE.
Citation Format: Lynch MC, Mankoff D, Bradbury AR, Domchek S, Glick JH, Matro J, DeMichele A, Clark AS. Flourine-18-fluorodeoxyglucose positron emission tomography for the evaluation of response to therapy in bone-dominant metastatic breast cancer: Examination in patients enrolled on UPCC 17113. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-01-02.
Collapse
Affiliation(s)
- MC Lynch
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - D Mankoff
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - AR Bradbury
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - S Domchek
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - JH Glick
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - J Matro
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - A DeMichele
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - AS Clark
- Hospital of the University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
34
|
Clark AS, O'Dwyer P, Troxel A, Lal P, Feldman M, Gallagher M, Driscoll A, Colameco C, Lewis D, Rosen M, Matro J, Bradbury A, Domchek S, Fox K, DeMichele A. Abstract P6-13-08: Palbociclib and paclitaxel on an alternating schedule for advanced breast cancer: Results of a phase Ib trial. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-13-08] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Palbociclib (P) is an oral CDK 4/6 inhibitor (CDKi) that was recently FDA approved in combination with endocrine therapy for metastatic breast cancer. We have performed a Phase I trial of P in combination with paclitaxel (T) based on preclinical studies suggesting that P synergizes with T when given on an alternating schedule, enabling cell cycle synchronization in tumor cells. We now present the dose expansion cohort.
Methods: Patients (Pts) enrolled on the trial had Rb-expressing tumors of any estrogen/progesterone/HER2 receptor type, adequate organ function, and ≤3 prior chemotherapy regimens for metastatic breast cancer (mBC). Prior adjuvant or metastatic taxane was allowed. Dose escalation led to expansion at P100mg or 75mg, starting with 3 days of P (run-in) and reduction of P dosing from 5-day to 3-day intervals (days 2-4, 9-11, 16-18 of each 28 day cycle). T at 80mg/m2 was given weekly for 3 cycles; thereafter, T was administered days 1, 8 and 15 of 28 day cycle. Weekly toxicity assessments were performed; RECIST 1.0 response was assessed every 2 cycles as partial response (PR), stable disease (SD) or progressive disease (PD). Pts had the option to discontinue T and continue on P alone (3 on/1 off schedule) if they attained SD after cycle 6.
Results: 27 pts enrolled on study (15- dose escalation, 12- dose expansion). Results are shown in the Table. 21 pts had received prior taxane; pts had received a median of 2 chemotherapy regimens for mBC. DLTs were grade 3 AST/ALT (n=1, at 125 mg) and febrile neutropenia (FN) (n=1, at 100 mg). Uncomplicated grade 3/4 NTP was common and frequently led to dose reduction or dose interruption during the first cycle of therapy. Frequency of NTP did not change with reducing the days of P. Among 24 evaluable patients, 14 (58%), had PR or SD ≥ 6 months across all dose levels. Of 14 pts who responded, 10 (71%) had received prior taxane. 20 pts are off study; 19 for PD, and 2 for toxicity (NTP in cycle 17 and FN in cycle 1); 7 pts remain on study. Prolonged tumor responses were seen.
Conclusions: P and T can be safely combined on an alternating dosing schedule; the optimal combination dose is 75 mg of P and 80mg/m2 of weekly T. The high response rate warrants a randomized trial to determine the incremental benefit over T alone. Additional mechanistic studies are in progress to understand the in vivo effects of the alternating dosing schedule on cell cycle activity and tumor proliferation.
Starting Dose Level P (mg)Number (Total 27)DLTGrade 3/4 NTP (n)Final Dose P mg (n)Dose Interruption (n)Best Response (n)5030050 (1) 50 (1) 50 (1)No (2) Yes (1)PR (1) SD (1) PD (1)7530275 (1) 50 (1) 25 (1)No (1) Yes (2)PR (2) SD (1)100605100 (2) 75 (3) 25 (1)No (1) Yes (5)PR (2) SD (1) PD (3)12531- LFT375 (1) 50 (2)No (0) Yes (3)PR (1) SD (2)75 (Run-In)60175 (5) 50 (1)No (4) Yes (2)PR (1) SD (2) PD (1) N/A (2)*100 (Run-In)61- FN5100 (1) 75 (4) 25(1)No (1) Yes (5)PR (4) SD (1) N/A (1)^*2 pts not yet evaluable. ^1 pt went off study due to FN after cycle 1.
Citation Format: Clark AS, O'Dwyer P, Troxel A, Lal P, Feldman M, Gallagher M, Driscoll A, Colameco C, Lewis D, Rosen M, Matro J, Bradbury A, Domchek S, Fox K, DeMichele A. Palbociclib and paclitaxel on an alternating schedule for advanced breast cancer: Results of a phase Ib trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-13-08.
Collapse
Affiliation(s)
- AS Clark
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - P O'Dwyer
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - A Troxel
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - P Lal
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - M Feldman
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - M Gallagher
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - A Driscoll
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - C Colameco
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - D Lewis
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - M Rosen
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - J Matro
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - A Bradbury
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - S Domchek
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - K Fox
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - A DeMichele
- Perelman School of Medicine, University of Pennsylvania; Division of Hematology/Oncology, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
35
|
Albain KS, Leyland-Jones B, Symmans F, Paoloni M, van 't Veer L, DeMichele A, Buxton M, Hylton N, Yee D, Lyandres Clennell J, Yau C, Sanil A, Berry D, Esserman L. Abstract P1-14-03: The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-14-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: I-SPY 2 is a multicenter phase 2 trial using response-adaptive randomization within biomarker subtypes to evaluate a series of novel agents when added to standard neoadjuvant therapy for women with high-risk stage II/III breast cancer. The primary endpoint is pathologic complete response (pCR). The goal is to identify/graduate regimens with ≥85% Bayesian predictive probability of success (statistical significance) in a 300-patient phase 3 neoadjuvant trial defined by hormone-receptor (HR), HER2 status & MammaPrint (MP). Regimens may also leave the trial for futility (< 10% probability of success) or following accrual of maximum sample size (10%< probability of success <85%). We report the results for trebananib, an angiopoietin-1/2-neutralizing peptibody that inhibits interaction with the Tie2 receptor.
Methods: Women with tumors ≥2.5cm were eligible for screening. MP low/HR+/HER2- tumors were ineligible for randomization. Serial MRI scans (baseline, 2 during treatment and pre-surgery) were used in a longitudinal model to improve the efficiency of adaptive randomization. Participants are categorized into 8 subtypes based on: HR status, HER2 status and MP High 1 (MP1) or High 2 (MP2). MP1 and MP2 are determined by a predefined median cut-point of I-SPY 1 participants who fit the eligibility criteria for I-SPY 2. Trebananib was initially assigned to HER2- patients only; once safety data with trastuzumab (H) were obtained, it was also assigned to HER2+ patients. Analysis was intent to treat -- patients who switched to non-protocol therapy were designated non-pCRs.
Results: Trebananib +/-H did not meet the criteria for graduation in any of the 10 signatures tested. When the maximum sample size was reached, accrual ceased. We report probabilities of trebananib +/-H being superior to control and Bayesian predictive probabilities of success in a 1:1 randomized neoadjuvant phase 3 trial for the 10 biomarker signatures, using the final pCR data from all patients.
SignatureEstimated pCR Rate (95% probability interval)Probability Trebananib Is Superior to ControlPredictive Probability of Success in Phase 3Trebananib (n=134)Control (n=133)ALL0.259(0.16 -0.36)0.158(0.09-0.23)0.9860.564HR+0.157(0.05-0.26)0.115(0.03- 0.20)0.8050.281HR-0.378(0.22-0.53)0.207(0.11- 0.31)0.9910.784HER2+0.279(0.07-0.49)0.17(0.04-0.30)0.8790.553HER2-0.254(0.15-0.36)0.155(0.08-0.23)0.9810.555MP20.342 (0.19-0.49)0.177(0.07-0.28)0.9910.786HR-/HER2-0.368 (0.21-0.53)0.201(0.10-0.30)0.9880.771HR-/HER2+0.444(0.15-0.74)0.244(0.07-0.42)0.9260.739HR+/HER2+0.201(0.01-0.39)0.135(0.01-0.26)0.7750.41HR+/HER2-0.143(0.04-0.24)0.11(0.03-0.19)0.7580.248
Citation Format: Albain KS, Leyland-Jones B, Symmans F, Paoloni M, van 't Veer L, DeMichele A, Buxton M, Hylton N, Yee D, Lyandres Clennell J, Yau C, Sanil A, I-SPY 2 Trial Investigators, Berry D, Esserman L. The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-14-03.
Collapse
Affiliation(s)
- KS Albain
- Loyola University, Chicago Stritch School of Medicine; Avera Medical Group; University of Texas, M.D. Anderson Cancer Center; QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania, Perelman School of Medicine; University of Minnesota, Masonic Cancer Center; Berry Consultants
| | - B Leyland-Jones
- Loyola University, Chicago Stritch School of Medicine; Avera Medical Group; University of Texas, M.D. Anderson Cancer Center; QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania, Perelman School of Medicine; University of Minnesota, Masonic Cancer Center; Berry Consultants
| | - F Symmans
- Loyola University, Chicago Stritch School of Medicine; Avera Medical Group; University of Texas, M.D. Anderson Cancer Center; QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania, Perelman School of Medicine; University of Minnesota, Masonic Cancer Center; Berry Consultants
| | - M Paoloni
- Loyola University, Chicago Stritch School of Medicine; Avera Medical Group; University of Texas, M.D. Anderson Cancer Center; QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania, Perelman School of Medicine; University of Minnesota, Masonic Cancer Center; Berry Consultants
| | - L van 't Veer
- Loyola University, Chicago Stritch School of Medicine; Avera Medical Group; University of Texas, M.D. Anderson Cancer Center; QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania, Perelman School of Medicine; University of Minnesota, Masonic Cancer Center; Berry Consultants
| | - A DeMichele
- Loyola University, Chicago Stritch School of Medicine; Avera Medical Group; University of Texas, M.D. Anderson Cancer Center; QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania, Perelman School of Medicine; University of Minnesota, Masonic Cancer Center; Berry Consultants
| | - M Buxton
- Loyola University, Chicago Stritch School of Medicine; Avera Medical Group; University of Texas, M.D. Anderson Cancer Center; QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania, Perelman School of Medicine; University of Minnesota, Masonic Cancer Center; Berry Consultants
| | - N Hylton
- Loyola University, Chicago Stritch School of Medicine; Avera Medical Group; University of Texas, M.D. Anderson Cancer Center; QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania, Perelman School of Medicine; University of Minnesota, Masonic Cancer Center; Berry Consultants
| | - D Yee
- Loyola University, Chicago Stritch School of Medicine; Avera Medical Group; University of Texas, M.D. Anderson Cancer Center; QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania, Perelman School of Medicine; University of Minnesota, Masonic Cancer Center; Berry Consultants
| | - J Lyandres Clennell
- Loyola University, Chicago Stritch School of Medicine; Avera Medical Group; University of Texas, M.D. Anderson Cancer Center; QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania, Perelman School of Medicine; University of Minnesota, Masonic Cancer Center; Berry Consultants
| | - C Yau
- Loyola University, Chicago Stritch School of Medicine; Avera Medical Group; University of Texas, M.D. Anderson Cancer Center; QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania, Perelman School of Medicine; University of Minnesota, Masonic Cancer Center; Berry Consultants
| | - A Sanil
- Loyola University, Chicago Stritch School of Medicine; Avera Medical Group; University of Texas, M.D. Anderson Cancer Center; QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania, Perelman School of Medicine; University of Minnesota, Masonic Cancer Center; Berry Consultants
| | - D Berry
- Loyola University, Chicago Stritch School of Medicine; Avera Medical Group; University of Texas, M.D. Anderson Cancer Center; QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania, Perelman School of Medicine; University of Minnesota, Masonic Cancer Center; Berry Consultants
| | - L Esserman
- Loyola University, Chicago Stritch School of Medicine; Avera Medical Group; University of Texas, M.D. Anderson Cancer Center; QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania, Perelman School of Medicine; University of Minnesota, Masonic Cancer Center; Berry Consultants
| | | |
Collapse
|
36
|
DeMichele A, Shih NNC, Koehler M, Huang Bartlett C, Jiang Y, Harwick J, Huang D, Zheng X, Clark AS, Colameco C, Feldman MD, Gallagher M, Goodman N, O'Dwyer P, Rejto P. Abstract P4-13-04: Upregulation of cell cycle pathway genes without loss of RB1 contributes to acquired resistance to single-agent treatment with palbociclib in breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-13-04] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The oral cdk4/6 inhibitor, Palbociclib (Palbo), has been shown to prolong progression-free survival when combined with anti-estrogen therapy and have single-agent activity in metastatic breast cancer (MBC). Progressive disease (PD) on therapy does occur, however, and little is known about resistance mechanisms. Preclinical data have suggested that cell cycle gene expression changes are a potential mechanism of resistance. We performed comprehensive genomic analyses on serial tumor samples from an exceptional responder to single-agent Palbo to determine whether such changes occur in vivo.
Methods: Serial biopsies were obtained from a 67 year old patient with MBC treated on a phase II trial of single-agent Palbo at the University of Pennsylvania. Tissue was obtained from the primary lesion (1999, Stage 3, ER-/PR+/Her2+) and first recurrence (2005, contralateral breast, bone, lung; ER+/PR-/Her2+, treated with Herceptin/letrozole). At PD (2010), pt received single-agent P, 50 mg daily for 21 days each 28-day cycle, with PR for 33 months. A sample from metastatic skin lesion at PD on P (2013) was obtained. Next generation targeted sequencing was performed at Foundation Medicine using the Heme Panel. RNA was profiled using a 784-gene custom Nanostring array including cell cycle genes and ER pathway genes. Determination of pathway enrichment was performed using GSEA and the statistical significance of network neighborhood over-representation was calculated using cumulative hypergeometric distribution.
Results: There was no genetic evidence suggesting loss of RB1, or alterations in p16, cyclin D1, cdk4, PIK3CA or ESR1, and the genomic profile did not change between the primary and recurrent tissue samples. As expected, amplification of ERRB2 was present in all samples. In contrast, expression of cell cycle-regulated genes (PLK1, TOP2A, CDK1, BUB1, CDC20, CCNA2, CCNE2, CCNB1 BIRC5) increased more than two-fold at PD on Palbo compared to pre-Palbo, along with evidence of activation of the FOXM1 network.
Conclusion: Gene expression changes associated with cell cycle activation and FOXM1 activation may lead to acquired resistance to Palbociclib, despite wild-type RB1. These data demonstrate the importance of pre-/post-treatment biopsies and the feasibility of high-level genomic assessment in archival tissues to elucidate resistance mechanisms of novel therapies.
Citation Format: DeMichele A, Shih NNC, Koehler M, Huang Bartlett C, Jiang Y, Harwick J, Huang D, Zheng X, Clark AS, Colameco C, Feldman MD, Gallagher M, Goodman N, O'Dwyer P, Rejto P. Upregulation of cell cycle pathway genes without loss of RB1 contributes to acquired resistance to single-agent treatment with palbociclib in breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-13-04.
Collapse
Affiliation(s)
- A DeMichele
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| | - NNC Shih
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| | - M Koehler
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| | - C Huang Bartlett
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| | - Y Jiang
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| | - J Harwick
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| | - D Huang
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| | - X Zheng
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| | - AS Clark
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| | - C Colameco
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| | - MD Feldman
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| | - M Gallagher
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| | - N Goodman
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| | - P O'Dwyer
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| | - P Rejto
- University of Pennsylvania School of Medicine, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA; Pfizer Oncology, NY, NY; Pfizer Oncology Research, San Diego, CA
| |
Collapse
|
37
|
Liu MC, Symmans WF, Yau C, Chen YY, Rugo HS, Olopade OF, Datnow B, Chen B, Feldman M, Kallakury B, Hasteh F, Tickman R, Ritter J, Troxel M, Mhawech-Fauceglia P, Duan X, Berry D, Esserman L, DeMichele A. Abstract P3-07-49: Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-07-49] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: I-SPY2 is a multicenter phase 2 trial in high risk stage II/III breast cancer (BC) using adaptive randomization within biomarker subtypes to evaluate novel agents added to standard neoadjuvant chemotherapy. The first regimen to graduate based on the predicted probability of a higher pCR rate within predefined subsets was veliparib/carboplatin + paclitaxel (VC+T→AC vs T→AC) in triple negative BC (TNBC). In TNBC the residual cancer burden (RCB) is prognostic, whether as a continuous index or grouped into classes, with pCR (RCB-0) and RCB-I classes having identical survival. Therefore, we evaluated the use of RCB to further discriminate between investigational and control arms.
Methods: Site pathologists reported RCB for 99% of subjects in the primary efficacy analysis based on pCR (n=114/115). We compared the distribution of RCB reported as a continuous index in each treatment-subset combination to matched concurrently randomized controls using the Wilcoxon rank sum test for RCB index, and Fisher's Exact test for RCB classes (RCB-0/I vs RCB-II/III). The statistics are descriptive rather than inferential, and given the small sample size have no claim on generalizability. We modified the Bayesian model used to compute the estimated probability of success in a future, randomized, phase 3 trial of 300 subjects, if response were defined by either pCR or RCB-I (RCB0/I), or separately if it were defined by pCR alone.
Results: VC+T→AC led to a significantly lower RCB index than T→AC in TNBC (p=0.0021), with a near-significant trend when those with pCR were excluded (p=0.06). There was no significant difference in RCB distributions in the other breast cancer subtypes treated. In TNBC, the odds ratio (OR) for achieving RCB-0/I in the VC+T→AC arm vs control was 8.2 (95% confidence interval (CI): 2.1–35), whereas the OR for achieving pCR was 4.56 (95% CI: 1.25–19.53). The simulations using response information from I-SPY2 to predict the probability of success for VC+T→AC for TNBC in a future phase 3 trial estimated this probability to be 0.99 if modeled using RCB-0/I as the response endpoint, and 0.90 if modeled using pCR as the response endpoint.
Conclusions: Use of RCB index and classes provided additional insight into the effect of adding VC to T, appearing to magnify the improved treatment response that had been observed with pCR rates in TNBC. It will be important to test in randomized trials whether a decrease in the RCB index relative to controls, and/or increased rates of RCB-0/I class, are predictive of survival benefit in TNBC.
Citation Format: Liu MC, Symmans WF, Yau C, Chen Y-Y, Rugo HS, Olopade OF, Datnow B, Chen B, Feldman M, Kallakury B, Hasteh F, Tickman R, Ritter J, Troxel M, Mhawech-Fauceglia P, Duan X, Berry D, Esserman L, DeMichele A. Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-49.
Collapse
Affiliation(s)
- MC Liu
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - WF Symmans
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - C Yau
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - Y-Y Chen
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - HS Rugo
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - OF Olopade
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - B Datnow
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - B Chen
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - M Feldman
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - B Kallakury
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - F Hasteh
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - R Tickman
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - J Ritter
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - M Troxel
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - P Mhawech-Fauceglia
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - X Duan
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - D Berry
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - L Esserman
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| | - A DeMichele
- Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA; University of Chicago, Chicago, IL; University of San Diego, San Diego, CA; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Swedish Medical Center, Seattle, WA; University of Minnesota, Minneapolis, MN; OHSU, Portland, OR; Keck Hospital of USC, Los Angeles, CA; Loyola University Health System, Mayowood, IL
| |
Collapse
|
38
|
Soucier-Ernst D, Colameco C, Troxel AB, Clark C, Shih N, Maxwell KN, Morrissette J, Lieberman D, Feldman M, Goodman N, Bradbury A, Clark A, Domchek S, Fox K, Glick J, Matro J, Nathanson K, Chodosh L, DeMichele A. Abstract P6-07-05: Mutational spectrum and tumor response in metastatic breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-07-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: While several comprehensive genomic sequencing tests are clinically available for breast cancer(BC), little is known about the spectrum of findings reported in the general population and clinical utility of findings for patients(pts). Here we report tumor sequencing from the METAMORPH study, a comprehensive genomic testing approach in pts with metastatic(met) BC.
Methods: Pts with either known or suspected BC mets consented to and clinically underwent concurrent diagnostic and research tumor biopsies(bx). FFPE specimens were profiled via Illumina TruSeq Cancer Panel next generation sequencing platform covering 212 amplicons in 47 cancer genes. Pathology, treatment and outcome data were prospectively collected and tracked. Aside from Her2-directed treatment, therapy was not mutation (mut)-matched.
Results: 64 pts enrolled between 11/2013 – 05/2015. Of these, 48 had bx successfully sequenced (75%). Of those without sequencing, 5 had negative/insufficient tissue, 2 had insufficient DNA, remainder no bx/pending. Median age of those sequenced was 56 (range 31-78); 81% Caucasian, 17% African American. 25% (12 pts) presented with de novo stage IV disease. Of those with recurrence (n=36), 83% had prior adjuvant chemotherapy; 81% hormone receptor positive(HR+) had prior endocrine therapy. Median # prior lines of therapy for met disease was 2 (IQR 0 – 8). Tumor characteristics, including mut analyses, are shown in Table 1. # muts did not differ significantly by subtype(p=0.22). Frequency of TP53 and PIK3CA hotspot muts was nearly identical to TCGA. Median # muts was 1 for pts with both de novo mets and recurrence(p=0.79). # of muts was not associated with time to recurrence(p=0.80). Excluding pts found to have TP53 mut only or ERBB2 alterations in known Her2+ disease, 42% of pts were identified as having at least one potentially actionable alteration (PIK3CA mut, AKT1 mut or EGFR amplification). Median time to treatment failure(TTF) on subsequent therapy was 4.1 months for overall group, and 4.1, 6.2, and 1.6 months for HR+/Her2-, any Her2+ and TN, respectively, adjusted for line of therapy(p=0.03). After adjustment for # lines of prior met therapy, TTF was 4.7 vs. 4.1 months for pts with any mut vs. none(p=0.89); 5.7 vs 4.1 months for PIK3CA+ vs. not (p=0.94); 3.3 vs. 6.5 months for TP53+ vs. not (p=0.03).
Conclusion: Pts with met BC have frequent and potentially actionable muts.While overall # of muts did not affect response, tumors with TP53 muts had shorter response to subsequent therapy in this cohort. Additional data are needed to determine the clinical utility of mut testing in met BC, for both standard and mut-matched therapy.
Total (n=48)HR+/Her2- (n=28)Any HER2+ (n=7)TN (n=13)Receptor concordant with primary 100%78%77%# Mutations Median (Range)1 (0-4)1 (0-3)1 (1-2)1 (0-4)014 (29%)10 (36 %)04 (31%)118 (38%)11 (39%)4 (57%)3 (23%)213 (27%)5 (18%)3 (43%)5 (38%)3+3 (6%)2 (7%)01 (8%)Prevalent Mutations (>20%)TP53 (38%), PIK3CA (35%)PIK3CA (50%), TP53 (25%)TP53 (60%), ERBB2amp (86%)TP53 (62%),PIK3CA (23%)Other Alterations (#)ATM (1), KIT (1), PDGFRA (1), PTEN(1), RB1 (1), SMAD4 (1), SMO (1), STK11 (1)AKT1 (1), ATM VUS (1), ERBB2 (1), PTEN (1), SMAD4 VUS (1), SMO VUS (1)ERBB2 (1), STK11(1)EGFR amp (2), KIT amp (1),PDGFRA amp (1), RB1 VUS (1)
Citation Format: Soucier-Ernst D, Colameco C, Troxel AB, Clark C, Shih N, Maxwell KN, Morrissette J, Lieberman D, Feldman M, Goodman N, Bradbury A, Clark A, Domchek S, Fox K, Glick J, Matro J, Nathanson K, Chodosh L, DeMichele A. Mutational spectrum and tumor response in metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-07-05.
Collapse
Affiliation(s)
| | - C Colameco
- University of Pennsylvania, Philadelphia, PA
| | - AB Troxel
- University of Pennsylvania, Philadelphia, PA
| | - C Clark
- University of Pennsylvania, Philadelphia, PA
| | - N Shih
- University of Pennsylvania, Philadelphia, PA
| | - KN Maxwell
- University of Pennsylvania, Philadelphia, PA
| | | | - D Lieberman
- University of Pennsylvania, Philadelphia, PA
| | - M Feldman
- University of Pennsylvania, Philadelphia, PA
| | - N Goodman
- University of Pennsylvania, Philadelphia, PA
| | - A Bradbury
- University of Pennsylvania, Philadelphia, PA
| | - A Clark
- University of Pennsylvania, Philadelphia, PA
| | - S Domchek
- University of Pennsylvania, Philadelphia, PA
| | - K Fox
- University of Pennsylvania, Philadelphia, PA
| | - J Glick
- University of Pennsylvania, Philadelphia, PA
| | - J Matro
- University of Pennsylvania, Philadelphia, PA
| | - K Nathanson
- University of Pennsylvania, Philadelphia, PA
| | - L Chodosh
- University of Pennsylvania, Philadelphia, PA
| | - A DeMichele
- University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
39
|
Palmer SC, DeMichele A, Glanz K, Schapira M, Pucci DA, Blauch AN, Jacobs LA. Abstract P4-10-11: Comparability of computerized and paper-pencil patient reported outcome (PRO) assessments – Does it matter how they are administered? Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-10-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction:
There is an increased need to monitor and intervene to assist breast cancer (BC) survivors overcome the long-term and late effects of treatment. Many institutions are moving toward computerized assessments (CA) of PROs such as symptoms and concerns in place of more traditional paper and pencil administration, but little work has been performed to demonstrate that these very different methods of administration produce comparable results. Our goal was to evaluate the outcomes produced by these methods by comparing two similar samples of breast cancer survivors, one of which completed a PROs assessment using paper and pencil (PP), the other of which was assessed using a computerized system that links to the patient portal in use at our facility. Data collection of the CA of PROs is ongoing.
Method:
Women were eligible if they had a confirmed diagnosis of Stage 0-III BC, were within one year of completion of primary therapy, and were scheduled for a survivorship-focused end of treatment visit. As this was a naturalistic cohort study, no randomization was undertaken. The PRO assessment covered 19 common long-term or late effects of treatment, inquiring about their occurrence and severity in the previous month. On the day of the visit, participants in the PP cohort were provided with the questionnaire packet to complete prior to meeting with their provider. The women who completed the CA were either already enrolled in the patient portal or enrolled at the time of recruitment and sent an online version of the same questionnaire. Reminder calls and/or emails were sent to the CA participants to improve compliance.
Results:
164 BC survivors completed the PP questionnaire, and 62 women completed the CA. Racial make-up, marital status, and education, were similar between groups. Women in the PP group were older than those in the CA group (55.45 vs. 51.23 yrs, p < 0/05) and those in the PP group were marginally more likely than those in the CA group to have been menopausal prior to treatment (50% vs. 35%, p = 0.05).
With respect to PROs, there were no significant differences between groups in either the proportion of women endorsing a given symptom/concern or in the mean severity rating for any symptom/concern. The five most commonly reported concerns did differ somewhat between groups, with PP reporting Fatigue, Insomnia, Hot Flashes, Aching Joints, and Memory Difficulties, respectively, and CA reporting Fatigue, Anxiety, Body Image Problems, Memory Difficulties, and a tie between Insomnia and Depression, respectively.
Conclusion:
The results of the PRO assessment can be assumed to be comparable whether the method of administration is either PP or computerized. Differences found between groups in the most commonly endorsed symptoms likely reflected differences in age and menopausal status.
Citation Format: Palmer SC, DeMichele A, Glanz K, Schapira M, Pucci DA, Blauch AN, Jacobs LA. Comparability of computerized and paper-pencil patient reported outcome (PRO) assessments – Does it matter how they are administered?. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-10-11.
Collapse
Affiliation(s)
- SC Palmer
- Univeristy of Pennsylvania, Philadelphia, PA
| | - A DeMichele
- Univeristy of Pennsylvania, Philadelphia, PA
| | - K Glanz
- Univeristy of Pennsylvania, Philadelphia, PA
| | - M Schapira
- Univeristy of Pennsylvania, Philadelphia, PA
| | - DA Pucci
- Univeristy of Pennsylvania, Philadelphia, PA
| | - AN Blauch
- Univeristy of Pennsylvania, Philadelphia, PA
| | - LA Jacobs
- Univeristy of Pennsylvania, Philadelphia, PA
| |
Collapse
|
40
|
Jacobs LA, DeMichele A, Glanz K, Schapira M, Pucci DA, Blauch AN, Palmer SC. Abstract OT3-03-02: Assessment of cancer Concerns at the End of treatment (ACE): What do survivors need and want? Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot3-03-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Discussion:
There are over 14 million cancer survivors in the United States today and this population will continue to grow. Not only are survivors at risk for recurrence, but increasingly complex treatments place them at risk for a range of long-term and late effects. Provision of survivorship care plans (SCPs) at an end of treatment (EOT) visit that includes referrals to appropriate resources may be assumed to improve the care provided to survivors. There are, however, few relevant studies examining the outcomes of providing patients with referrals to resources identified through the completion of patient reported outcomes (PROs) reported in the literature. Current research has focused on documenting the frequency with which SCPs are provided and the perceived usefulness of these documents. Such data are a necessary but an insufficient step in the creation of practice guidelines in part guided by PROs, or standards of care that support the provision of SCPs. This study will provide a comprehensive description of breast cancer (BC) survivors' symptom burden and other concerns, as well as health behaviors as they enter the survivorship phase of care. These items will be evaluated by data generated by a pre visit PROs questionnaire completed through the patient portal. Significant symptoms and concerns will be addressed during a clinical encounter at the EOT visit. It will also describe referrals triggered by these data.
Trial Design:
Quasi-experimental single-group design with historical controls. Our study describes patient-reported symptom burden, desire for assistance, quality of life (QoL) and health behaviors of BC survivors who have completed initial treatment using a web-based platform to collect PRO data. As well, it estimates differences in referral and uptake between participants and historical controls.
Eligibility Criteria:
Survivors must understand English, have internet access and a working email address, and be age 18 years or older within 1 year of completing initial treatment (chemotherapy, radiotherapy, and/or surgery). Participants may still be receiving hormonal or targeted therapy.
Specific Aims:
1) Describe physical and psychosocial PROs of BC survivors after completion of treatment so as to define targets and develop metrics for future intervention; 1A) examine diagnosis and treatment variables that moderate PROs; 2) determine provider satisfaction with a web based patient questionnaire that includes a summary of significant patient concerns; 3) estimate the impact of providing the summary of patient concerns on utilization of/referral to available services relative to historic controls.
Statistical Methods:
Parameter estimates with confidence intervals for concerns and desire for help. Bivariate associations between unmet needs and quality of life. Non-parametric comparison of referral patterns between ACE participants and historical controls.
Present Accrual and Target:
To date 107 BC survivors have consented to complete a self-report survey questionnaire prior to their scheduled EOT visit, 61 completed the survey, 28 pending a visit. Target 250.
Citation Format: Jacobs LA, DeMichele A, Glanz K, Schapira M, Pucci DA, Blauch AN, Palmer SC. Assessment of cancer Concerns at the End of treatment (ACE): What do survivors need and want?. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT3-03-02.
Collapse
Affiliation(s)
- LA Jacobs
- University of Pennsylvania, Philadelphia, PA
| | - A DeMichele
- University of Pennsylvania, Philadelphia, PA
| | - K Glanz
- University of Pennsylvania, Philadelphia, PA
| | - M Schapira
- University of Pennsylvania, Philadelphia, PA
| | - DA Pucci
- University of Pennsylvania, Philadelphia, PA
| | - AN Blauch
- University of Pennsylvania, Philadelphia, PA
| | - SC Palmer
- University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
41
|
Affiliation(s)
- A S Clark
- Department of Medicine, Division of Hematology/Oncology, Abramson Cancer Center
| | - A DeMichele
- Department of Medicine, Division of Hematology/Oncology, Abramson Cancer Center Center for Clinical Epidemiology and Biostatistics
| | - D Mankoff
- Division of Nuclear Medicine, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
| |
Collapse
|
42
|
Homer M, Charo L, Natarajan L, Haunschild C, DeMichele A, Su I. Predicting menopause in breast cancer survivors: an analysis of 13 single nucleotide polymorphisms. Fertil Steril 2015. [DOI: 10.1016/j.fertnstert.2015.07.328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
43
|
Charo L, Homer M, Natarajan L, Haunschild C, DeMichele A, Su I. Drug metabolizing enzme polymorphisms are associated with chemotherapy related amenorrhea in young breast cancer survivors. Fertil Steril 2015. [DOI: 10.1016/j.fertnstert.2015.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
44
|
Melichar B, DeMichele A, Adenis A, Bourbouloux E, Tan-Chiu E, Niu H, Schusterbauer C, Dansky Ullmann C, Zhang B, Benaim E. Abstract PD5-5: Phase 2 study of single agent MLN8237 (alisertib), an investigational aurora A kinase (AAK) inhibitor, in patients (pts) with relapsed/refractory breast cancer (BrC). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-pd5-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: AAK, a key mitotic regulator, is frequently amplified/overexpressed across a spectrum of tumors, including BrC. AAK overexpression is associated with poor prognosis. MLN8237 is an oral selective AAK inhibitor under evaluation in pts with advanced cancer as a single agent and in combination therapy. A phase 1/2 study (NCT01045421) evaluated MLN8237 in pts with different solid tumors; phase 2 data for the Brc cohort are presented.
Methods: Females aged ≥18 y with relapsed/refractory BrC including HR+, HER2+ and triple-negative histological subtype, ECOG PS 0–1, measurable disease by RECIST v1.1 and ≤4 prior cytotoxic chemotherapy regimens (not including adjuvant, neo-adjuvant; no limitation on prior hormonal or HER2 targeted, immunological or biological agents) were enrolled. Symptomatic brain metastases were excluded (treated stable metastasis allowed). A Simon's optimal 2-stage design was used; 20 pts were initially enrolled, expansion proceeded if ≥2 objective responses were observed in these response-evaluable pts. Pts received MLN8237 50 mg BID for 7 days in 21-day cycles. Primary objective: overall response rate (ORR). Secondary objectives: safety, duration of response (DOR) and progression-free survival (PFS). An exploratory study was performed to assess clinical responses in relation to candidate biomarker dysregulation (mutation, amplification, and deletion) in banked tumor specimens.
Results: As of April, 2013, 53 pts were enrolled: median age was 60 y (range 33–81), median of 4 cycles (range 1–21). 49 pts (92%) were response-evaluable (HR+, n = 26; HER2+, n = 9; triple negative, n = 14). 33% of pts received treatment for ≥6 months (HR+, n = 11 [69%]; HER2+, n = 3 [19%]; triple negative, n = 2 [12%]). ORR (all pts) was 18% and median PFS was 5.42 months. Efficacy data per subgroup are shown in the table. All 53 pts were included in the safety population; drug-related adverse events (AEs) were reported in 51 pts (96%), most frequent were neutropenia (55%), alopecia (49%) and diarrhea (45%). 38 pts (72%) had grade ≥3 drug-related AEs, including neutropenia (49%), leukopenia (21%) and febrile neutropenia (4%). G-CSF use was 32%. 2 pts (4%) discontinued due to AEs (sepsis [grade 4], n = 1; neutropenia [grade 3], n = 1); no on-study deaths were reported. Treatment is ongoing in 3 HR+ pts. Whole-exome sequencing of selected tumor samples was completed. Correlative analysis is ongoing to identify potential genetic markers/mutated pathways associated with clinical response. Preliminary results will be presented.
Conclusions: MLN8237 appears to have a generally manageable toxicity profile and shows signs of single agent antitumor activity in pts with heavily pretreated (different molecular subgroups) of relapsed/refractory BrC supporting further evaluation of MLN8237 in this tumor type in different combination strategies.
Efficacy HR+ (n = 26)HER2+ (n = 9)Triple-negative (n = 14)Best response,%ORR (PR)23227Stable disease653336Progressive disease124457Median DOR, months4.2-*-**Median PFS, months7.94.11.5*2 events, **1 event
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr PD5-5.
Collapse
Affiliation(s)
- B Melichar
- Fakultní Nemocnice Olomouc – Onkologická Klinika, Olomouc, Czech Republic; University of Pennsylvania, Philadelphia, PA; Centre Oscar Lambret, Lille Cedex, France; Institut de Cancérologie de l'Ouest, Nantes, France; Plantation - Florida Cancer Research Institute (Florida Cancer Care), Plantation, FL; Millennium: The Takeda Oncology Company, Cambridge, MA
| | - A DeMichele
- Fakultní Nemocnice Olomouc – Onkologická Klinika, Olomouc, Czech Republic; University of Pennsylvania, Philadelphia, PA; Centre Oscar Lambret, Lille Cedex, France; Institut de Cancérologie de l'Ouest, Nantes, France; Plantation - Florida Cancer Research Institute (Florida Cancer Care), Plantation, FL; Millennium: The Takeda Oncology Company, Cambridge, MA
| | - A Adenis
- Fakultní Nemocnice Olomouc – Onkologická Klinika, Olomouc, Czech Republic; University of Pennsylvania, Philadelphia, PA; Centre Oscar Lambret, Lille Cedex, France; Institut de Cancérologie de l'Ouest, Nantes, France; Plantation - Florida Cancer Research Institute (Florida Cancer Care), Plantation, FL; Millennium: The Takeda Oncology Company, Cambridge, MA
| | - E Bourbouloux
- Fakultní Nemocnice Olomouc – Onkologická Klinika, Olomouc, Czech Republic; University of Pennsylvania, Philadelphia, PA; Centre Oscar Lambret, Lille Cedex, France; Institut de Cancérologie de l'Ouest, Nantes, France; Plantation - Florida Cancer Research Institute (Florida Cancer Care), Plantation, FL; Millennium: The Takeda Oncology Company, Cambridge, MA
| | - E Tan-Chiu
- Fakultní Nemocnice Olomouc – Onkologická Klinika, Olomouc, Czech Republic; University of Pennsylvania, Philadelphia, PA; Centre Oscar Lambret, Lille Cedex, France; Institut de Cancérologie de l'Ouest, Nantes, France; Plantation - Florida Cancer Research Institute (Florida Cancer Care), Plantation, FL; Millennium: The Takeda Oncology Company, Cambridge, MA
| | - H Niu
- Fakultní Nemocnice Olomouc – Onkologická Klinika, Olomouc, Czech Republic; University of Pennsylvania, Philadelphia, PA; Centre Oscar Lambret, Lille Cedex, France; Institut de Cancérologie de l'Ouest, Nantes, France; Plantation - Florida Cancer Research Institute (Florida Cancer Care), Plantation, FL; Millennium: The Takeda Oncology Company, Cambridge, MA
| | - C Schusterbauer
- Fakultní Nemocnice Olomouc – Onkologická Klinika, Olomouc, Czech Republic; University of Pennsylvania, Philadelphia, PA; Centre Oscar Lambret, Lille Cedex, France; Institut de Cancérologie de l'Ouest, Nantes, France; Plantation - Florida Cancer Research Institute (Florida Cancer Care), Plantation, FL; Millennium: The Takeda Oncology Company, Cambridge, MA
| | - C Dansky Ullmann
- Fakultní Nemocnice Olomouc – Onkologická Klinika, Olomouc, Czech Republic; University of Pennsylvania, Philadelphia, PA; Centre Oscar Lambret, Lille Cedex, France; Institut de Cancérologie de l'Ouest, Nantes, France; Plantation - Florida Cancer Research Institute (Florida Cancer Care), Plantation, FL; Millennium: The Takeda Oncology Company, Cambridge, MA
| | - B Zhang
- Fakultní Nemocnice Olomouc – Onkologická Klinika, Olomouc, Czech Republic; University of Pennsylvania, Philadelphia, PA; Centre Oscar Lambret, Lille Cedex, France; Institut de Cancérologie de l'Ouest, Nantes, France; Plantation - Florida Cancer Research Institute (Florida Cancer Care), Plantation, FL; Millennium: The Takeda Oncology Company, Cambridge, MA
| | - E Benaim
- Fakultní Nemocnice Olomouc – Onkologická Klinika, Olomouc, Czech Republic; University of Pennsylvania, Philadelphia, PA; Centre Oscar Lambret, Lille Cedex, France; Institut de Cancérologie de l'Ouest, Nantes, France; Plantation - Florida Cancer Research Institute (Florida Cancer Care), Plantation, FL; Millennium: The Takeda Oncology Company, Cambridge, MA
| |
Collapse
|
45
|
Clark AS, Lal P, Tan KS, Heitjan DF, Feldman M, Zhang P, Gallagher M, Domchek S, Gogineni K, Keefe S, Fox KR, O'Dwyer P, DeMichele A. Abstract P2-16-20: Biomarkers to predict response to the CDK 4/6 inhibitor, palbociclib (PD 0332991) in a single-agent phase II trial in advanced breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-16-20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The Cyclin D1-CDK4/6 complex is critical in regulating the G1/S checkpoint and phosphorylation of retinoblastoma protein (Rb); palbociclib is a highly-selective CDK 4/6 inhibitor. CCND1, the gene encoding Cyclin D1, is amplified in 15% of breast tumors; p16, the endogenous inhibitor of the complex is lost in up to half of breast tumors. We hypothesized that breast tumors containing either alteration or a high proliferative rate would have enhanced sensitivity to palbociclib. We conducted a single-agent, phase II trial of palbociclib in patients with advanced breast cancer (UPCC03909). In this trial, the clinical benefit rate (partial response [PR] + stable disease ≥6 months [6mSD]) was 17% (DeMichele, ASCO, 2013). The current analysis was a secondary endpoint to determine whether Rb expression, p16 loss, Ki-67 index or CCND1 amplification predicted response in the phase II trial.
Methods: Enrollment on UPCC03909 required archival tumor collection from either primary tumor or metastatic lesions. Fresh frozen paraffin-embedded (FFPE) tumor sections were tested for expression of Rb, Ki-67 and p16 by immunohistochemistry (IHC), and CCND1 amplification by fluorescence in situ hybridization. Categorical variables based on% tumor staining and intensity scores (negative defined as 0 or 1+ intensity staining, equivocal defined as 2+ staining or 3+ in <30%, or positive defined as 3+ staining intensity in 30%) were generated for Rb and p16 nuclear staining. Fisher's Exact test was used to test for associations between nominal factors, the Cochran-Mantel-Hænszel test for associations between ordinal factors, and the Cox proportional hazard model for association of progression-free survival (PFS) with biomarkers.
Results: Thirty-seven patients were enrolled; response evaluation is available in 36/37. All had FFPE tumor available for Rb, 33/37 (89%)for CCND1 amplification and 29/37 (78%) for Ki-67 and p16 analyses. For complete results see Table 1.
Conclusions: These results provide preliminary evidence that breast tumors more likely to respond to palbociclib may have higher Rb nuclear expression, lower Ki67 indices and/or loss of p16. Larger studies are needed to confirm these results.
Table 1: Biomarker Summary and ResponseBiomarkerBiomarker CategoizationFrequency (%)Response Rate PR+6mSD/total (%)PFS Hazard Ratio (95%CI)Overall Population (n = 37) 6/36 (17%) Ki-67 (n = 29)≤ 10 (n = 20)69%4/19 (21%)1.00 > 10 (n = 9)31%1/9 (11%)1.20 (0.50, 2.88)Rb (n = 37)Nuclear Score: Negative (n = 11)30%0/11 (0%)1.00 Equivocal (n = 15)40%2/14 (14.3%)0.72 (0.28, 1.84) Positive (n = 11)30%4/11 (36.4%)0.71 (0.28, 1.80)p16 (n = 29)Loss or Low Expression (n = 16)55%4/16 (25%)1.00 Moderate or High Expression (n = 13)45%1/12 (8.3%)1.08 (0.47, 2.49)CCND1 Amplification (n = 34)Non-amplified (n = 25)88%4/25 (16%)1.00 Amplified (n = 9)12%1/8 (12.5%)1.06 (0.46, 2.4)
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-16-20.
Collapse
Affiliation(s)
- AS Clark
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; Pfizer, New York, NY
| | - P Lal
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; Pfizer, New York, NY
| | - KS Tan
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; Pfizer, New York, NY
| | - DF Heitjan
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; Pfizer, New York, NY
| | - M Feldman
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; Pfizer, New York, NY
| | - P Zhang
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; Pfizer, New York, NY
| | - M Gallagher
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; Pfizer, New York, NY
| | - S Domchek
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; Pfizer, New York, NY
| | - K Gogineni
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; Pfizer, New York, NY
| | - S Keefe
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; Pfizer, New York, NY
| | - KR Fox
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; Pfizer, New York, NY
| | - P O'Dwyer
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; Pfizer, New York, NY
| | - A DeMichele
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; Pfizer, New York, NY
| |
Collapse
|
46
|
DeMichele A, Yee D, Hylton N, Vant'Veer L, Symmons W, Perlmutter J, Lyandres J, Davis S, Buxton M, Berry D, Esserman L. SP005 Rationale of the design of the I-SPY trial. Eur J Cancer 2013. [DOI: 10.1016/s0959-8049(13)70083-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
47
|
Haunschild C, Sammel M, Chung K, DeMichele A, Su H. Pre-chemotherapy levels of follicle stimulating hormone and anti-mullerian hormone predict time to return of ovarian function in young breast cancer patients. Fertil Steril 2013. [DOI: 10.1016/j.fertnstert.2013.07.1814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
48
|
Su HI, Flatt SW, Natarajan L, DeMichele A, Steiner AZ. Erratum to: Impact of breast cancer on anti-mullerian hormone levels in young women. Breast Cancer Res Treat 2013. [DOI: 10.1007/s10549-013-2492-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
49
|
Alvarez RH, DeMichele A, Mailliez A, Benaim E, Fingert H, Schusterbauer C, Zhang B, Melichar B. Abstract P6-10-02: MLN8237 (alisertib), an investigational Aurora A Kinase inhibitor, in patients with breast cancer: Emerging phase 2 results. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-10-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Aurora A Kinase (AAK) is a key mitotic regulator amplified or overexpressed in a variety of tumor types including pre-invasive and invasive breast cancer. In mouse mammary epithelium, AAK overexpression induces genetic instability and tumor formation. In breast cancer patients (pts), AAK overexpression is often associated with poor prognosis. Therefore, AAK is an attractive target in cancer treatment. MLN8237 is an oral, selective AAK inhibitor under evaluation in pts with different advanced tumors. An ongoing multi-indication phase 2 (NCT01045421) trial evaluates MLN8237 in pts with solid tumors; here we present preliminary phase 2 data on the breast cancer cohort.
Methods: Eligible pts were female ≥18 years of age with stage IV breast cancer, ECOG PS 0–1, measurable disease by RECIST, and ≤4 prior cytotoxic chemotherapy regimens. Stratification on receptor subtype was performed to ensure 8–10 pts with triple negative disease and 8–10 patients with HER2 positive disease. Oral MLN8237 50 mg was administered twice-daily for 7 days, followed by 14 days' rest in 21-day cycles. The primary objective was overall response rate; response was determined by RECIST v1.1. Secondary objectives included assessment of safety. A Simon's optimal 2-stage design was used; 20 pts were initially enrolled, and this cohort was expanded if ≥2 partial responses (PR) were observed in response-evaluable pts.
Results: In the first 20 pts, 2 had PR and the cohort was expanded to a total of 53 (data cut-off: March 29, 2012). Median age was 60 years (range 33–81). Pts received a median of 3 cycles (range 1–14) and 20 pts (38%) received ≥6 treatment cycles. Of 45 response-evaluable pts, 6 pts (13%) had a best response of PR and 26 (58%) had stable disease (SD). Median duration of SD was 68 days, of which 2 pts (4%) had SD for ≥6 months (clinical benefit rate [PR+SD ≥6 months] = 18%). One HER2+ patient with 2 prior lines of therapy (carboplatin/docetaxel/trastuzumab + trastuzumab maintenance; gemcitabine/lapatinib/ trastuzumab) had PR 6 months. Fifty-three pts were evaluable for toxicity. Drug-related adverse events (AEs) were reported in 49 pts (92%) and were commonly grade 1–2 in severity. The most frequent drug-related AEs included alopecia (n = 26, 49%), neutropenia (n = 25, 47%), diarrhea (n = 23, 43%), fatigue (n = 21, 40%), and stomatitis (n = 19, 36%). A total of 34 pts (64%) reported grade ≥3 drug-related AEs, including neutropenia (n = 23, 43%) and leukopenia (n = 8, 15%). Two pts (4%) discontinued due to AEs; there were no on-study deaths. Treatment is ongoing in 21 pts.
Conclusions: Emerging phase 2 data reported here provide preliminary evidence of antitumor activity of oral MLN8237 in pts with relapsed/refractory breast cancer. AEs were frequent but generally reversible and manageable by dose reduction and supportive care.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-10-02.
Collapse
Affiliation(s)
- RH Alvarez
- The University of Texas MD Anderson Cancer Center, Houston, TX; Abramson Cancer Center, Philadelphia, PA; Centre Oscar Lambret, Lille, Cedex 59, France; Millennium Pharmaceuticals, Inc., Cambridge, MA; Fakultní nemocnice Olomouc - Onkologická klinika, Olomouc, Czech Republic
| | - A DeMichele
- The University of Texas MD Anderson Cancer Center, Houston, TX; Abramson Cancer Center, Philadelphia, PA; Centre Oscar Lambret, Lille, Cedex 59, France; Millennium Pharmaceuticals, Inc., Cambridge, MA; Fakultní nemocnice Olomouc - Onkologická klinika, Olomouc, Czech Republic
| | - A Mailliez
- The University of Texas MD Anderson Cancer Center, Houston, TX; Abramson Cancer Center, Philadelphia, PA; Centre Oscar Lambret, Lille, Cedex 59, France; Millennium Pharmaceuticals, Inc., Cambridge, MA; Fakultní nemocnice Olomouc - Onkologická klinika, Olomouc, Czech Republic
| | - E Benaim
- The University of Texas MD Anderson Cancer Center, Houston, TX; Abramson Cancer Center, Philadelphia, PA; Centre Oscar Lambret, Lille, Cedex 59, France; Millennium Pharmaceuticals, Inc., Cambridge, MA; Fakultní nemocnice Olomouc - Onkologická klinika, Olomouc, Czech Republic
| | - H Fingert
- The University of Texas MD Anderson Cancer Center, Houston, TX; Abramson Cancer Center, Philadelphia, PA; Centre Oscar Lambret, Lille, Cedex 59, France; Millennium Pharmaceuticals, Inc., Cambridge, MA; Fakultní nemocnice Olomouc - Onkologická klinika, Olomouc, Czech Republic
| | - C Schusterbauer
- The University of Texas MD Anderson Cancer Center, Houston, TX; Abramson Cancer Center, Philadelphia, PA; Centre Oscar Lambret, Lille, Cedex 59, France; Millennium Pharmaceuticals, Inc., Cambridge, MA; Fakultní nemocnice Olomouc - Onkologická klinika, Olomouc, Czech Republic
| | - B Zhang
- The University of Texas MD Anderson Cancer Center, Houston, TX; Abramson Cancer Center, Philadelphia, PA; Centre Oscar Lambret, Lille, Cedex 59, France; Millennium Pharmaceuticals, Inc., Cambridge, MA; Fakultní nemocnice Olomouc - Onkologická klinika, Olomouc, Czech Republic
| | - B Melichar
- The University of Texas MD Anderson Cancer Center, Houston, TX; Abramson Cancer Center, Philadelphia, PA; Centre Oscar Lambret, Lille, Cedex 59, France; Millennium Pharmaceuticals, Inc., Cambridge, MA; Fakultní nemocnice Olomouc - Onkologická klinika, Olomouc, Czech Republic
| |
Collapse
|
50
|
DeMichele A. Abstract ES3-2: Clinical Trial Designs for New Therapies: What Agents Should We Study? Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-es3-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Biologically-targeted, novel agents hold great promise in breast cancer, but require adjustments to traditional study design, conduct and patient selection to be tested safely, effectively and economically. Key questions to be address in this talk include: Is the drug safe? Is it hitting the target? Can we identify the “right” patients to test? In what setting do we test it? Toxicities of these agents move well-beyond traditional myelosuppression and fatigue, encompassing almost every organ system and requiring changes in monitoring and management to assure safety. Dosing and assessment strategies must be aimed at optimally modulating target and assessing whether hitting the target has the desired effect on the natural history of the disease. The concurrent development of predictive biomarkers is necessary to select appropriate study subjects, which may be limited to a relatively small subset of patients with the disease. Finally, selecting the best therapeutic setting (treatment naïve, refractory, acquired resistance) can greatly impact the performance of the agent and requires knowledge of cancer biological evolution through the metastatic process.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr ES3-2.
Collapse
Affiliation(s)
- A DeMichele
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| |
Collapse
|